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1. SYNOPSIS 
 
Background 
In contemporary clinical practice, measurement of circulating biomarkers is an 
integral part of patient care. Biomarkers have many areas of application and provide 
diagnostic, prognostic and therapeutic information. The appropriate use of biomarkers 
can facilitate the understanding of underlying pathophysiological processes and may 
contribute to improved management of various disease states. 
 
Aim 
The aim of this thesis was to explore novel aspects of circulating biomarkers 
associated with cardiovascular disease, with an emphasis on myocardial infarction 
(MI) and obstructive sleep apnea (OSA).  
 
Methods 
In a retrospective, national, single-center, pre-post comparison study of hospital 
admissions, changes in non-ST-segment elevation myocardial infarction (NSTEMI) 
diagnostics after the implementation of a high-sensitivity cardiac troponin T (hs-
cTnT) assay were examined. In a post hoc analysis of patients with acute ST-segment 
elevation myocardial infarction (STEMI) treated with primary percutaneous coronary 
intervention (PCI) who participated in a prospective, international, multi-center, 
randomized placebo-controlled trial, the utility of cardiac troponin I (cTnI) variables 
for prediction of clinical outcomes and cardiac function during three months follow-
up were investigated. In a national, single-center, cross-sectional study of individuals 
examined for possible OSA, circulating levels of several biomarkers (myocardial 
stress; single-molecule cTnI [S-cTnI] and hs-cTnT, inflammation; myeloid-related 
protein-8/14 and C-reactive protein) and their associations to variables of disordered 
breathing during sleep were explored. 
 
Results 
An increase of primary NSTEMI admissions after the implementation of a high-
sensitivity assay was observed, while a higher proportion of the subjects did not have 
pathological findings on coronary angiography and fewer had significant dynamic 
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cTnT changes. In patients with STEMI, cTnI levels were associated with an increased 
risk of clinical events and decreased cardiac function at three months independent of 
clinical risk factors. Furthermore, cTnI significantly improved discrimination of 
patients with and without endpoint. In individuals investigated for possible OSA, the 
application of novel cardiac troponin (cTn) assays facilitated estimation of myocardial 
stress in all subjects. No independent associations between apnea-hypopnea index and 
myocardial stress or inflammation were found after adjustment for other risk factors, 
whereas oxygen variables were observed to inherit a heterogeneous pattern of selected 
independent associations. The association between several of the variables of 
disordered breathing during sleep and inflammation was stronger in individuals with a 
higher body mass index (BMI). 
 
Interpretation and conclusion 
The introduction of a hs-cTnT assay enhanced NSTEMI diagnostics, but more 
patients will have to be considered for potentially having increased cTnT levels due to 
other etiologies than MI. In STEMI patients, the present findings imply that one 
single measurement of cTnI after PCI provides incremental information to 
conventional risk stratification. In individuals investigated for possible OSA, the use 
of S-cTnI and hs-cTnT confirmed that improved performance characteristics are 
broadening potential applications of cTn assays. For the diagnostic evaluation of 
possible OSA, the future clinical utility of all investigated biomarkers appears limited. 
However, the observed interaction between a higher BMI and several variables of 
disordered breathing during sleep may indicate activated inflammatory pathways 
inconsistently masked by unmeasured confounders or too moderate to be significant 
in this study sample. These findings expand our knowledge of the investigated 
biomarkers and contribute to determine their future role in patient care.
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3. ABBREVATIONS 
 
AHI  Apnea-hypopnea index 
AUC  Area under curve 
BMI  Body mass index 
CAD  Coronary artery disease 
CHF  Congestive heart failure 
CI  Confidence interval 
CPAP  Continuous positive airway pressure 
CRP  C-reactive protein 
cTn  Cardiac troponin 
CV  Coefficient of variation 
CVD  Cardiovascular disease 
ECG  Electrocardiogram 
EMG  Electromyogram 
hs-cTnT High-sensitivity cardiac troponin T 
IDI  Integrated discrimination improvement 
MI  Myocardial infarction 
MRP-8/14 Myeloid-related protein-8/14 
NSTEMI Non-ST-segment elevation myocardial infarction 
NT-proBNP N-terminal pro-B-type natriuretic peptide 
LoB  Limit of blank 
LoD  Limit of detection 
LoQ  Limit of quantification 
LVEF  Left ventricular ejection fraction 
ODI  Oxygen desaturation index 
OSA  Obstructive sleep apnea 
PCI  Percutaneous coronary intervention 
PG  Polygraphy 
PSG  Polysomnography 
S-cTnI  Single-molecule cardiac troponin I 
STEMI ST-segment elevation myocardial infarction
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5. BACKGROUND 
 
5.1 Cardiovascular disease 
Cardiovascular disease (CVD) is the number one cause of death globally (1). CVD is 
defined as a group of disorders involving the heart or blood vessels (2). Myocardial 
infarction (MI) and obstructive sleep apnea (OSA) are two distinct disease entities 
related to CVD; MI is a captious and potentially lethal manifestation of coronary 
artery disease (CAD), whereas evidence suggests that patients with OSA have an 
increased risk of developing CAD and several other CVDs (3-5). As the most 
frequent cause of death out of all CVDs, 7.3 million people died due to CAD 
worldwide in 2008 (6). 
 
5.2 Myocardial infarction 
History and Epidemiology 
Since MI was identified as a distinct clinical entity by James B. Herrick in 1912, with 
the mainstay of treatment being "absolute bed rest" (7), a remarkable evolution in the 
understanding of MI´s pathophysiological basis has occurred. Considerable 
improvements have been made to prevention, detection and treatment of the disease. 
Despite these substantial developments, MI yearly afflicts more than 7 million people 
worldwide and remains associated with considerable morbidity and mortality (8). 
 
Pathophysiology 
MI is generally preceded by years of gradually progressive and asymptomatic CAD. 
The process is termed atherosclerosis of the coronary arteries, where plaque builds up 
within the vessel walls (9). Initially considered a cholesterol-storage disorder, many 
now regard atherosclerosis an inflammatory disease resulting from a complex 
pathophysiological interplay between several factors (10). Components of lipid 
metabolism, inflammation and various cell types within the lesion have been 
identified as contributors in experimental studies (11). Risk factors for the condition 
include dyslipidemia, hypertension, smoking and hyperglycemia (12). When 
atherosclerosis progresses it may lead to narrowing of the vessel lumen and reduced 
blood flow to the myocardium (9). However, it is also a major pathophysiological 
component in the archetypal MI. In this setting, acute thrombus formation takes place 
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in a coronary artery following atherosclerotic plaque disruption (13). Normal blood 
flow to the myocardium is either hindered by the thrombus obtruding the artery lumen 
or by embolic debris lodged in distal blood vessels. Subsequently, ischemia ensues 
and myocyte necrosis occurs (14). Nevertheless, through advances in our 
understanding of the underlying processes, as well as the development of refined tools 
to detect, quantify and visualize infarcted myocardium, it has now been established 
that other mechanisms than thrombus formation in an atherosclerotic artery may also 
contribute to MI. In the current “Third Universal Definition of Myocardial 
Infarction”, several distinct types of MI´s are characterized based on pathological, 
clinical and prognostic differences (Table 1) (14). 
 
Table 1. Types of myocardial infarction. 
Type Description 
1 
Spontaneous myocardial infarction related to a primary coronary event 
with resulting intraluminal thrombus, such as plaque rupture or dissection. 
2 
Myocardial infarction resulting from imbalance between oxygen supply 
and/or demand, such as coronary artery spasm or arrhythmias. 
3 Myocardial infarction resulting in death when biomarkers are unavailable. 
4a Myocardial infarction related to percutaneous coronary intervention. 
4b Myocardial infarction related to stent thrombosis. 
4c 
Myocardial infarction related to restenosis following initially successful 
stent deployment or balloon angioplasty. 
5 Myocardial infarction related to coronary artery bypass grafting. 
 
Diagnostic assessment 
An acute MI is defined by “evidence of myocardial necrosis in a clinical context 
consistent with myocardial ischemia” (14). Consequently, the interpretation of 
symptoms and signs of potential ischemia, in combination with the detection of 
necrosis, formulate the key elements during patient assessment. Over the past 
decades, the diagnostic evaluation has changed quite substantially. This has mainly 
been driven by extensive improvements in the laboratorial methods used to establish 
the presence of myocardial necrosis (15).  
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Observing a pattern of rising and/or falling cardiac biomarker levels, with at 
least one measurement being above the 99th percentile concentration value in a normal 
reference population, has been an essential diagnostic criterion for many years (16-
18). Nevertheless, due to suboptimal precision at lower concentration levels for the 
earlier generations of cardiac troponin (cTn) assays, some have advocated for the use 
of a higher cut-off point (19). Accordingly, there has been considerable variation in 
applied cut-off points across centers (20). However, with the improved performance 
characteristics of recently developed cTn assays, it is expected that their use in 
clinical practice will lead to greater adherence to the 99th percentile guideline 
recommendation. With more widespread use of this cut-off point, it is likely that the 
number of patients being diagnosed with MI will increase (21-23). In parallel, the 
prevalence of observed cardiac biomarker elevations due to other causes is anticipated 
to escalate (15,21,24). Consequently, the improved diagnostic sensitivity that follows 
the use of these assays will be accompanied by poorer specificity. To avoid 
misdiagnosing patients with cardiac biomarker elevations from other mechanisms 
than ischemic myocardial necrosis, it is therefore important that at least one of the 
following additional criteria1 is fulfilled (14): (1) Symptoms of ischemia; (2) new (or 
presumably new) significant ST/T wave changes or left bundle branch block; (3) 
development of pathological Q waves on electrocardiogram (ECG); (4) imaging 
evidence of new loss of viable myocardium or regional wall motion abnormality; (5) 
identification of intracoronary thrombus by angiography or autopsy. 
 
Prognostic assessment 
Several characteristics have been associated with a poor prognosis in MI patients. 
This has led to the development of risk scores used to stratify individuals. The risk 
can be determined based on findings at admission (25-28), or upon discharge when 
incremental information obtained during hospitalization can be incorporated (29-32). 
These scores are well-validated tools used to assess in-hospital and long-term risk of 
mortality, or a composite of recurrent ischemia and mortality. Demographic 
information, prior medical history, findings from physical examination, ECG changes 

1 These criteria are used when a MI diagnosis is based on the detection of a rise and/or fall of 
cardiac biomarker values with at least one value above the 99th percentile upper reference limit. MI 
resulting in cardiac death when biomarkers are unavailable, MI related to percutaneous coronary 
intervention, MI related to stent thrombosis, MI related to restenosis, MI related to coronary artery 
bypass grafting and prior MI are diagnosed based on other criteria specific to each of these entities 
(14). 
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and biochemical biomarkers are typical important indicators. In addition, variables 
such as angiography findings, estimates of left ventricular function and occurrence of 
adverse events during the hospital admission may be included. However, they do not 
encompass measures of infarct size, which has been indicated as an important 
determinant of chronic left ventricular dysfunction and adverse events following MI 
(33,34). The elements of one such validated risk score for 30-day mortality in ST-
segment elevation myocardial infarction (STEMI) are provided in Table 2 (25). 
 
Table 2. TIMI Risk Score for STEMI. 
Characteristic Points 
Age  65-74 
 ≥75 
2 
3 
Diabetes, hypertension or angina 1 
Systolic blood pressure <100 mmHg 3 
Heart rate >100 bpm 2 
Killip class II-IV 2 
Weight <67 kg 1 
Anterior ST elevation or left bundle branch block 1 
Time to treatment >4 hours 1 
Maximum score 14 
 
5.3 Obstructive sleep apnea 
History and epidemiology 
While the clinical picture of alveolar hypoventilation syndromes as a character trait 
has been recognized for a long time, a proper understanding of their pathophysiology 
did not transpire until the 20th century. The “Pickwickian syndrome”, a condition 
closely related to OSA, was first introduced as a term by Sir William Osler in 1918 
(35). Obesity, hypersomnolence, periodic breathing with hypoventilation and cor 
pulmonale were later defined as the classical features of this syndrome (36). 
However, the interaction between respiration and sleep was not recognized to be of 
considerable importance until “multiple respiratory pauses during sleep" were 
recorded with a polysomnograph in 1965 (37). Shortly thereafter, “sleep-induced 
apneas” were documented in non-obese individuals and the first symposium on sleep-
related respiratory problems established a new concept of “sleep-induced apnea 
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syndromes” in 1972 (38). The pathophysiology and clinical ramifications have since 
been subject to increased focus in the medical community. Today, OSA is regarded a 
distinct clinical entity among several different “sleep related breathing disorders” 
(39). It is a common condition more frequent with men and older age groups. 
Depending on the population studied and the definition applied for the diagnosis, the 
typical adult prevalence ranges from 2% to 30% (40-42). 
 
Pathophysiology 
OSA is characterized by repetitive abnormal breathing giving rise to disrupted 
ventilation during sleep (43). A recurrent collapse of the upper airway results in 
partial (hypopnea) or complete (apnea) cessation of airflow despite ongoing 
respiratory effort (Figure 1). This leads to intermittent disturbances in gas exchange 
and fragmented sleep (44). One respiratory event typically lasts 20-40 seconds and 
can occur more that 100 times per hour in severe cases (45). Components that likely 
underpin the occurrence or severity of OSA include upper airway anatomy, the ability 
of the upper airway dilator muscles to respond to respiratory challenge during sleep, 
arousal threshold, body habitus, stability of the respiratory control system and the 
potential for state-related changes in lung volume to influence these factors (45,46). 
Studies have indicated that obesity, increasing age and male gender are among the 
more significant predictors for the condition (43,47,48). 
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Figure 1. The upper airway in normal breathing and obstructive sleep apnea. 
 
Adapted from the Mayo Clinic website. Reproduced with permission. 
© Mayo Foundation for Medical Education and Research. 
 
Cardiovascular consequences 
In patients with OSA, the cardiovascular system is repetitively exposed to cycles of 
hypoxia, exaggerated negative intrathoracic pressure and arousal (44). This 
conglomerate of noxious stimuli may lead to depressed myocardial contractility, 
activation of the sympathetic nervous system, raised blood pressure, heart rate and 
myocardial wall stress, depressed parasympathetic activity, provoked oxidative stress 
and systemic inflammation, impaired vascular endothelial function, activated platelets 
and hypercoagulability (5). While the specific processes are still subject to research, 
current understanding suggests that at least some of these mechanisms contribute to 
causal pathways of CVD (Figure 2) (5,44,49). This is further supported by data 
indicating a significant association between OSA and several CVDs (3,4). Also, 
studies have demonstrated a lower risk or improvement of various surrogate markers 
in association with continuous positive airway pressure (CPAP) treatment (50-55). 
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Figure 2. Possible mechanisms resulting from noxious stimuli in obstructive sleep 
apnea. 
 
 
5.4 Biomarkers 
The National Institutes of Health Biomarkers Definitions Working Group has defined 
a biomarker as "a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes or pharmacologic 
responses to a therapeutic intervention" (56). Biomarkers can be classified into 
categories according to their inherent properties. Consequently, a “CVD biomarker” 
may be used to broadly address an indicator of a pathophysiological process 
implicated in CVD. Alternatively, an “inflammatory biomarker” may be used to 
describe a mechanism more explicitly.  
The term "biomarker" is usually associated with measurements of substances 
in tissues or body fluids (57). However, it is evident from the definition that it 
encompasses a wide range of characteristics. This includes anything from body 
weight, blood pressure and heart rate to more complex metrics of ECG recordings and 
echocardiograms. It is essential that a biomarker can be “objectively measured”, 
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which implies that the obtained measure is accurate and reproducible. In the case of 
blood samples, the following criteria have been proposed as properties of an ideal 
biomarker (58,59): (1) An accurate, reproducible assay should be available at a 
reasonable cost and have acceptable turnaround time; (2) the assay should be highly 
sensitive and specific for the outcome it is expected to identify, and the test result 
should explain a reasonable proportion of the outcome independent of established 
predictors; (3) the test should be acceptable and understandable to the patient, and the 
test results should be easily interpretable by clinicians; (4) very importantly, 
knowledge of the biomarker´s levels should change patient management.  
Biomarkers have many areas of use, and they already do enable better 
management of numerous disease states in daily clinical practice. In fact, several 
established applications, such as blood pressure and cholesterol level measurements, 
have contributed to a steady decline in CVD morbidity and mortality in high-income 
countries over the past decades (60). Nevertheless, current projections indicate that 
this group of disorders will remain the leading cause of death worldwide (61). Thus, 
investigating additional aspects of biomarkers associated with CVD remains of 
considerable importance given the potential to further improve patient care. 
 
5.5 Cardiac troponin 
Troponin is a protein complex of three subunits. The units are named according to 
their function; the calcium binding subunit (TnC), the inhibitory subunit (TnI) and the 
tropomyosin-binding subunit (TnT) (62,63). Troponin regulates contraction and 
relaxation through modulation of the calcium-mediated interaction between actin and 
myosin in the human striated muscle (64). With TnI and TnT being expressed as 
cardio-specific isoforms generally considered unique to the myocardium (cTnT and 
cTnI), they are well suited for detection of heart muscle injury (65). Experimental 
data have suggested that cTn leaks from the cell only in instances of membrane 
disruption following myocyte necrosis (66). However, the detection of a brief rise and 
subsequent fall of cTn concentration during marathon running (67), as well as a rise 
after transient stress test-induced myocardial ischemia (68), has cast doubt on the 
hypothesis that cTn is released only upon irrevocable necrotic damage. In fact, 
various additional mechanisms have been suggested as causes for liberation of cTn 
from the myocardium. These include increased physiological cell turnover, apoptosis, 
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formation and release of membranous blebs, cellular release of troponin degradation 
products and increased cellular wall permeability (69). Cardiac troponin is currently 
the biomarker of choice for the diagnosis of MI due to superior sensitivity and 
specificity when compared to the alternative biomarkers for myocardial cell death 
(14). Typical release kinetics, with an early peak followed by a more prolonged, 
slowly abating plateau, can be observed following onset of infarction (Figure 3). 
While the peak is more influenced by cTn from a loosely bound pool, the second 
phase mainly originates from degradation of the contractile apparatus (18). A few out 
of many examples of other conditions associated with elevated cTn levels include 
heart failure, myocarditis, renal insufficiency and pulmonary embolism (Figure 4) 
(17,70). Thus, detection of circulating cTn molecules can also be applied more 
broadly as a biomarker of myocardial stress, but do not define the underlying cause 
(70). Consequently, in addition to being a central diagnostic aid in establishing MI, it 
has been shown that the biomarker possesses strong prognostic properties in several 
other CVDs (71). 
 
Figure 3. Cardiac troponin in myocardial infarction. 
 
Adapted and translated from Atar (15). Reproduced with permission. © Kari C. Toverud CMI (board 
Certified Medical Illustrator). 
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Figure 4. Examples of clinical entities associated with elevated cardiac troponin 
levels. 
 
 
5.6 Myeloid-related protein-8/14 and C-reactive protein 
Myeloid-related protein-8/14 (MRP-8/14) is a heterodimer with proinflammatory 
characteristics expressed by monocytes, neutrophils and platelets. It is a complex of 
two calcium-binding proteins that possess intra- and extracellular activity (MRP-8 
[S100A8] and MRP-14 [S100A9]). MRP-8 and MRP-14 are displayed by monocytes 
upon interaction with activated endothelium and reflect phagocyte stimulation 
(72,73). They are members of the S100 family of proteins, which is involved in the 
inflammatory response through, in part, activation of the receptor for advanced 
glycation end-products (74,75). In animal studies, MRP-8/14 is critical for the 
biological response to vascular injury (76). Thus, MRP-8/14 concentrations in plasma 
or serum may be a useful biomarker of inflammation (77). Circulating MRP-8/14 has 
previously been shown to be associated with inflammatory disorders and MI and to be 
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an independent predictor of cardiovascular events in healthy subjects and patients 
with acute coronary syndrome (72,78-83).  
C-reactive protein (CRP) is a homopentamer synthesized by hepatocytes in 
response to factors produced by adipose tissue and inflammatory cells (84-90). There 
have also been reports of potential CRP expression in other locations, including fat 
and the coronary artery smooth muscle (91-93). CRP has been implicated in several 
important host defense, scavenging and metabolic functions, particularly through its 
capacity to activate complement after binding exogenous and autologous molecules 
(84,85). For many years, it was considered a nonspecific acute-phase response to most 
forms of inflammation, infection and tissue damage, but has later also been 
established as a useful biomarker of chronic low-grade inflammatory activity (84). 
CRP has been shown to be an independent predictor of cardiovascular events in 
apparently healthy individuals and of recurring events or death in patients with 
established CVD (94-97).
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6. AIMS 
 
The aim of this thesis was to explore novel aspects of circulating biomarkers 
associated with CVD, with an emphasis on MI and OSA. 
 
Specific aims: 
 
• To examine characteristics of non-ST-segment elevation myocardial infarction 
(NSTEMI) diagnostics before and after the implementation of a high-
sensitivity cardiac troponin T assay (hs-cTnT) into clinical practice (paper I) 
 
• To determine the prognostic value of various cTnI variables for prediction of 
clinical outcomes and cardiac function during three months follow-up after 
primary PCI for STEMI (paper II) 
 
• In individuals investigated for possible OSA, to characterize myocardial stress 
by using a single-molecule cTnI (S-cTnI) and a hs-cTnT assay and explore the 
association to apnea-hypopnea index (AHI) and oxygen assessment variables 
recorded during polysomnography (PSG) or polygraphy (PG) (paper III) 
 
• In individuals investigated for possible OSA, to characterize inflammation by 
using a MRP-8/14 and a CRP assay and explore the association to AHI and 
oxygen assessment variables recorded during PSG or PG, as well as to 
investigate whether body mass index (BMI) interacts with these associations 
(paper IV)
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7. METHODS 
 
7.1 Sample and design 
Three study samples were used to explore novel aspects of biomarkers associated 
with CVD, with an emphasis on MI and OSA. 
 
Paper I 
Hospital admissions over two one-year periods were investigated in a retrospective, 
national, single-center, pre-post comparison study at Lovisenberg Diakonale 
Hospital´s medical department; the first period was from 1st of August 2007 to 31st 
of July 2008 (catchment´s population 145000 people) and the last period from 1st of 
August 2009 to 31st of July 2010 (catchment´s population 155000 people). A hs-
cTnT assay used for diagnostic assessment in the last period was introduced in the 
hospital on the 1st of April 2009, whereas a conventional cTnT assay was used in the 
first period. All registered hospital stays in the two periods were evaluated to compare 
the occurrence of primary NSTEMI admissions and various properties of these 
admissions. The study was conducted according to the principles of the Declaration of 
Helsinki and the Uniform Requirements for Manuscripts Submitted to Biomedical 
Journals by the International Committee of Medical Journal Editors. It was approved 
by the hospital´s local ethics committee and the privacy protection act supervisor. 
  
Paper II 
Subjects receiving PCI for STEMI in the prospective, international, multi-center, 
phase II, randomized placebo-controlled PROTECTION AMI trial were studied in a 
post hoc analysis. In this trial, patients with suspected STEMI presenting within 6 
hours of pain onset were included in 114 hospitals in 18 different countries between 
December 2008 and June 2010. Patients were randomized to the experimental agent 
delcasertib or placebo infusion on top of contemporary care. Follow-up endpoints 
included clinical events and assessment of cardiac function at three months. As no 
clear treatment effect of delcasertib had been observed, the randomization groups 
were combined in the present analysis. ECG inclusion criteria were ≥2 mm of ST 
elevation in at least two contiguous precordial leads (V1-V4) or ≥2 mm ST elevation 
in two inferior leads (II, III, aVF) with ST depression in two other contiguous leads 
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(total ≥8 mm ST deviation). Exclusion criteria included left bundle branch block or 
paced rhythm, prior coronary artery bypass grafting, persistent systolic blood pressure 
<90 mmHg unresponsive to intravenous fluids, fibrinolysis within 72 hours before 
presentation and end stage renal disease requiring dialysis. The protocol was 
approved at the institutional review board of each participating hospital, and all 
subjects provided written informed consent.  
 
Paper III and IV 
Consecutive individuals referred by general practitioners or Ear-Nose-Throat 
specialists to the sleep laboratory for evaluation of possible OSA from October 2009 
through February 2010 were considered for inclusion in a single-center, cross-
sectional study at Lovisenberg Diakonale Hospital. Participants were excluded if they 
had known OSA, if the sleep study indicated another type of sleep-disordered 
breathing than OSA or if there was no serum sampled for biobank (due to technical 
difficulties or if they did not consent). The study was conducted according to the 
principles of the Declaration of Helsinki and the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals by the International Committee of 
Medical Journal Editors. It was approved by the hospital´s local ethics committee, the 
privacy protection act supervisor, the Norwegian Directorate of Health and the 
regional ethics committee. All subjects provided written informed consent. 
 
7.2 Hospital admission data 
The hospital admission parameters evaluated in paper I were retrieved retrospectively. 
Discharge diagnoses had been coded for all medical department admissions by the 
treating physician using ICD-10 and, together with registered laboratorial data and 
selected demographics, this information was extracted from the hospital database by a 
blinded physician using Qlikview (Qlik Technologies Inc., Radnor, PA, USA).  
In all admissions with a registered diagnosis of MI (ICD-10 code I21 and I22), 
the DIPS electronic medical record system (DIPS ASA, Bodø, Norway) was then 
used to review patient charts and ECG recordings. This allowed for identification of 
primary NSTEMI admissions and registration of relevant pre-defined variables. A 
primary NSTEMI admission was defined if a patient with ECG findings not 
consistent with STEMI was admitted directly from the ambulance service, emergency 
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department, outpatient clinic, surgical department or general practitioner. All other MI 
stays, such as transfers from other hospitals, readmissions after coronary angiography 
investigations and others, were not eligible for classification as a primary NSTEMI 
admission. 
Coronary angiographies were performed at a secondary care facility (Oslo 
University Hospital) upon referral by the clinician, and were defined as acute if the 
patients were transferred directly from our hospital to the secondary care facility 
following a primary NSTEMI admission. The findings were classified using pre-
specified criteria by evaluating the written reports from these examinations. 
The highest cTnT level was defined as the highest concentration of measured 
cTnT during the hospital stay. To describe cTnT dynamics it was defined to calculate 
the relative change by using the lowest registered measurement before and after the 
highest concentration, with subsequent selection of the highest relative change from 
these two calculations. The biomarker characteristics were then categorized into pre-
specified groups to allow comparison. 
 
7.3 Clinical endpoints and cardiac function assessment 
PROTECTION AMI protocol-defined outcome data were used in paper II.  
Clinical endpoints (death, cardiogenic shock during the index hospitalization, 
congestive heart failure (CHF) or serious arrhythmia) were collected through three 
months follow-up. Cardiogenic shock during the index hospitalization was defined as 
a systolic blood pressure of <90 mmHg for >30 minutes or the need for supportive 
measures such as inotropic agents, in combination with evidence of end-organ 
hypoperfusion. CHF was defined if clinically present or developing ≥48 hours after 
admission (from Killip class I) or post-discharge if admitted to a health institution 
>12 hours for CHF. Serious arrhythmia was defined as sustained ventricular 
tachycardia >30 seconds occurring >48 hours after admission or ventricular 
fibrillation requiring pharmacologic treatment, external electrical cardioversion or 
cardiopulmonary resuscitation occurring >48 hours after admission. All clinical 
events were adjudicated by an independent committee. 
 Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were 
measured in all patients and left ventricular ejection fraction (LVEF) was estimated 
by multi gated acquisition scan in anterior infarctions for assessment of cardiac 
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function at three months. The results were analyzed and reported by central core 
laboratories. 
 
7.4 Sleep study 
Participants evaluated in paper III and IV were examined with overnight in-home PG 
or in-hospital PSG. The in-home, unattended PG was performed with a standard 10-
channel cardiorespiratory recording device (Embletta PDS, ResMed, Høvik, Norway) 
or a 12-channel monitor with a nasopharyngeal/oesophageal catheter measuring flow 
and pressure in the upper airways and indirectly the intrathoracic pressure (Reggie, 
Camtech, Høvik, Norway). The attended, in-hospital PSG (Embla S4500, ResMed) 
included a six-channel electroencephalogram, a two-channel electrooculogram, 
submental electromyogram (EMG), thoracic and abdominal movements (respiratory 
inductance plethysmography), air flow (nasal air pressure catheter), pulse oximetry, 
EMG from both legs, body position and a three-channel ECG.  
The data from the sleep study was scored by a qualified sleeping disorder 
specialist not involved in the study. A modified version of the 2007 American 
Academy of Sleep Medicine criteria for scoring respiratory events was used (98). 
Apnea was measured via transformed airflow signals from nasal pressure and defined 
as cessation of airflow ≥10 seconds. Hypopnea was defined as a 50% reduction in 
airflow with either a ≥3% oxyhemoglobin desaturation or an arousal or presumed 
arousal (an increase of 10% in heart rate). The AHI was calculated based on the total 
number of events per hour of total recording (PG) or sleep (PSG) time (movement 
time omitted). Oxygen desaturation index (ODI) was estimated by using the average 
number of desaturations of ≥3% per hour. 
OSA was defined as AHI ≥5 (symptoms of sleepiness were not considered).  
 
7.5 Biomarker analysis 
Cardiac troponin T (paper I and III) 
Electrochemiluminescent immunoassays on a Modular Analytics E170 platform from 
Roche Diagnostics (Roche, Basel, Switzerland) were used for analysis of cTnT at 
Lovisenberg Diakonale Hospital. The conventional assay was Elecsys® Troponin T 
(paper I) and the high-sensitivity assay was Elecsys® hs TnT (paper I and III). For the 
conventional assay, the manufacturer designates the lower detection limit at 10 ng/L, 
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the limit of quantification (LoQ) at 30 ng/L and the 99th percentile at <10 ng/L. For 
the high-sensitivity assay, the manufacturer designates the limit of blank (LoB) at <3 
ng/L, the limit of detection (LoD) at 5 ng/L, the LoQ at 13 ng/L and the 99th 
percentile at 14 ng/L (99). During in-house quality-control analyses, the laboratory 
found a coefficient of variation (CV) of 8.3% at a concentration of 72 ng/L with the 
conventional assay, and a CV of 4.7% at a concentration of 34 ng/L with the high-
sensitivity assay. 
 
Cardiac troponin I (paper II and III) 
A paramagnetic particle, chemiluminescent, two-site immunoenzymatic Access® 
AccuTnI® assay (Beckman Coulter, Fullerton, CA, USA) was used by a blinded core 
laboratory for analysis of cTnI (paper II). The assay has been reported to have a lower 
detection limit value at 0.006 g/L, a LoQ value at 0.014 g/L and a 99th percentile 
value at 0.04 g/L (100,101). Curve fitting was performed by a separate core 
laboratory according to a previously described methology for generation of peak and 
area under curve (AUC) values (102-104). Briefly, subjects had to have at least three 
values, one of which had to be drawn prior to the estimated peak, to derive a curve 
and determine estimated peak and AUC. 
 An Erenna system (Singulex, Inc., Alameda, CA, USA) based on 
microcapillary single-molecule counting combined with a microparticle immunoassay 
technology located at the Biomarker Research/TIMI Clinical Trials Laboratory 
(Brigham and Women’s Hospital, Boston, MA, USA) was used for the single-
molecule assay analysis of cTnI (paper III) (105). The assay has been standardized 
and validated in accordance with the National Institute of Standards and Technology 
material, with a reported LoB at <0.088 ng/L, a LoD at 0.091 ng/L, a LoQ at 0.88 
ng/L and a 99th percentile at 10.19 ng/L in a healthy reference population (106,107). 
 
Myeloid-related protein-8/14 (paper IV) 
Batch analysis of MRP-8/14 was performed at Lovisenberg Diakonale Hospital using 
a commercially available MRP8/14 enzymelinked immunosorbent kit (Bühlmann 
Laboratories AG, Schönenbuch, Switzerland). According to the manufacturer, this 
assay has an analytical range of 0.4–24 g/mL, an intra-assay CV of 4.3% (20 pairs of 
values from seven different serum samples each obtained in a single run) and an inter-
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assay CV of 5.8% (four samples each in 20 different runs). For a normal population, 
the expected median value for serum is 1.14 g/mL with a 95th percentile at 2.9 
g/mL (considered the upper limit of the normal reference range). These values were 
estimated by the manufacturer from apparently healthy male and female blood donors 
aged 18–70 years. All samples were analyzed in duplicates by an experienced 
biomedical laboratory scientist blinded to study data, with a reported average CV of 
4.0%. Readings <0.4 g/mL were interpreted as undetectable. 
 
C-reactive protein (paper IV) 
An immunoturbidimetric Tina-quant C-reactive Protein Gen. 3 (CRPL3) assay on a 
Modular Analytics P platform by Roche Diagnostics (Roche, Basel, Switzerland) was 
used for quantification of CRP at Lovisenberg Diakonale Hospital. According to the 
packet insert, this assay has an analytical range of 0.3–350 mg/L and a designated 
normal reference range <5 mg/L (108). The laboratory considered concentrations <1.0 
mg/L as undetectable, and reported between-run CVs of 2.3% at 4.3 mg/L and 2.9% 
at 73.2 mg/L. 
 
7.6 Statistical methods 
General statistics 
The data were approached statistically by a pre-defined limited set of analyses. 
 Continuous data are presented as mean ± standard deviation or median 
(quartile 1-3) depending on the distribution. Categorical data are presented as number 
and/or percent. Comparisons of continuous data were done using the two-sample t-
test (if normally distributed) or the Mann-Whitney U-test (if skewed). Categorical 
data were compared by the chi-square test, the Fisher´s exact test, the Fisher-Mid-P-
test or the Cochran-Armitage trend test. 
 Spearman rank correlation or simple median regression was used to assess 
univariable associations of variables. A cox proportional hazard, logistic or median 
regression was used to determine if variables were independent predictors of a 
dependent variable in multivariable models. The discriminative value of variables was 
explored by use of logistic regression models through comparison of C-statistics and 
evaluation of integrated discrimination improvement (IDI). 
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 A P-value of <0.05 was regarded statistically significant, and all hypothesis 
testing was two-tailed. 
 
Specific statistics 
In paper I, the denominators in categorical comparisons were the total number of 
medical department admissions not classified as a primary NSTEMI admission during 
each period (for the number of primary NSTEMI admissions and the number of acute 
angiographies), the total number of acute angiographies in each period (for the 
angiography findings) and the total number of primary NSTEMI admissions in each 
period (for the biomarker criteria). The statistical analyses were performed with 
OpenEpi (http://www.openepi.com/oe2.3/menu/openepimenu.htm) and PASW 
Statistics 18 (IBM SPSS Inc., Chicago, USA). 
 In paper II, multivariable models were applied to determine if cTnI variables 
(loge-transformed) were independent predictors of clinical outcomes, NT-proBNP and 
LVEF. Clinical risk factors comparable to the TIMI Risk Score assessment were used 
for adjustment and included age, female gender, hypertension, diabetes, prior heart 
failure, prior MI, systolic blood pressure, heart rate, weight, Killip class category, 
anterior infarct location and time from symptom onset to PCI (25). A clinical event 
composite (death, cardiogenic shock during the index hospitalization, CHF or serious 
arrhythmia), NT-proBNP >118 pmol/L (approximate threshold associated with 
increased risk in chronic heart failure) and LVEF <40% (moderate to severe reduction 
in left ventricular function) were used as dependent variables (109,110). Cox 
proportional hazards regression models were used to estimate hazard ratios and 95% 
confidence intervals (CI) for the time to clinical events. Logistic regression models 
were used to estimate odds ratios with 95% CIs for NT-proBNP >118 pmol/L or 
LVEF <40%. The discriminative properties of cTnI were explored by C-statistics of 
binary logistic regression models for the dependent variables (111). Each model 
containing a cTnI variable was compared to a model only containing clinical risk 
factors and bootstrapping was used to generate P-values. The IDI and relative IDI 
were also computed to quantify and test the contribution to predictive ability provided 
from each cTnI variable assessed (112,113). The statistical analyses were performed 
with the SAS System, version 9.2 (SAS Institute Inc., Cary, North Carolina, USA).  
 In paper III, multivariable median regression analyses were performed to 
investigate simultaneous associations of several predictors of S-cTnI or hs-cTnT and 
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in a final step AHI or an oxygen variable was forced into the model. The covariates 
used were age, male sex, BMI, hypertension, CVD, diabetes and estimated glomerular 
filtration rate. The statistical analyses were performed with PASW Statistics 18 (IBM 
SPSS Inc., Chicago, USA) and STATA version 12.1 (StataCorp LP, Texas, USA). 
 In paper IV, multivariable median regression analyses were performed to 
investigate simultaneous associations of several predictors of MRP-8/14 or CRP. 
Three models were designed to evaluate the characteristics of the potential 
associations between variables of disordered breathing during sleep and 
inflammation: (1) A baseline model to account for age and sex; (2) a BMI model to 
account for age, sex and BMI; (3) a final model to account for age, sex, BMI, systolic 
blood pressure, cholesterol:high-density lipoprotein ratio, glycosylated haemoglobin, 
smoking and CVD. The potential interaction between BMI and variables of 
disordered breathing during sleep on inflammation was probed by addition of an 
interaction term (variable of disordered breathing during sleep x BMI) to the final 
models. Undetectable values of MRP-8/14 (<0.4) and CRP (<1.0) were imputed using 
uniformly distributed random values on the intervals 0.0-0.4 (MRP-8/14) and 0.0-1.0 
(CRP). This imputation method was preferred after no noteworthy disagreements 
were observed when compared to sensitivity analyses using extreme case scenarios. 
The statistical analyses were performed with PASW Statistics 18 (IBM SPSS Inc., 
Chicago, IL, USA) and STATA version 12.1 (StataCorp LP, College Station, TX, 
USA). 
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8. RESULTS 
 
8.1 Paper I 
Characteristics of NSTEMI diagnostics before and after the implementation of a hs-
cTnT assay into clinical practice were examined. There was a significant increase in 
primary NSTEMI admissions when using the hs-cTnT assay (225 vs. 341, risk ratio 
1.57, 95% CI 1.33 to 1.85), and the number of coronary angiographies was higher (58 
vs. 81, P < 0.05). Furthermore, significantly more patients were examined without 
signs of coronary artery disease (CAD) (0% vs. 8.6%, P < 0.05), and a smaller 
proportion had significant dynamic cTnT changes between the highest and lowest 
cTnT measurement during each admission (96.2% vs. 88.7%, P < 0.01). 
 
8.2 Paper II 
The prognostic values of various cTnI variables for prediction of outcomes in 1066 
STEMI patients treated with primary PCI were determined. In adjusted models, all 
post-PCI single-points, peak and AUC were found to be independently associated 
with clinical events, NT-proBNP >118 pmol/L or LVEF <40% (P for all < 0.001). 
When cTnI was added individually to a baseline risk factor model for prediction of 
clinical events, the C-statistic improved from 0.779 to 0.846 (16-24 hours) and 0.859 
(70-80 hours). Quantified by the IDI, the addition of cTnI significantly augmented 
prediction ability (relative IDI 44-154%, P for all ≤ 0.001). Consistent improvements 
in discrimination of NT-proBNP >118 pmol/L and LVEF <40% were observed. 
 
8.3 Paper III 
Myocardial stress and its association to disordered breathing during sleep were 
characterized by use of novel cTn assays. All 222 (100%) individuals had detectable 
levels using either assay, and the patients with OSA (AHI ≥5, n = 161) had a different 
distribution of S-cTnI (P = 0.036) and hs-cTnT (P = 0.002) compared to those without 
(AHI <5, n = 61). However, in multiple median regression analyses adjusted for 
conventional predictors, neither S-cTnI (P = 0.57) nor hs-cTnT (P = 0.80) was 
significantly associated with AHI. Substituting oxygen variables with AHI in the 
multivariable models did not change the overall result for S-cTnI, whereas average 
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oxygen saturation (P = 0.009) and time <90% oxygen saturation (P = 0.017) remained 
statistically significantly associated with hs-cTnT. 
 
8.4 Paper IV 
Inflammation and its association to disordered breathing during sleep were 
characterized by use of MRP-8/14 and CRP assays. In baseline models (adjusted for 
age and sex), AHI was independently associated with MRP-8/14 (P = 0.025) and CRP 
(P < 0.001). The associations were attenuated after the addition of BMI, but remained 
statistically significant for CRP (P = 0.025). However, in final models adjusted for 
additional factors, only average oxygen saturation for MRP-8/14 (P = 0.028) and ODI 
for CRP (P = 0.037) remained independent predictors of inflammation, whereas AHI 
lost its predictive value (MRP-8/14; P = 0.30 and CRP; P = 0.092). The association 
between several variables of disordered breathing during sleep and inflammation was 
stronger in individuals with a higher BMI (P for interaction < 0.05 for AHI, nadir 
oxygen saturation and time <90% oxygen saturation).
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9. DISCUSSION 
 
9.1 Discussion of methods 
Sample and design 
Hospital admissions from two one-year periods were evaluated in a retrospective, 
national, single-center, pre-post comparison study in paper I. The retrospective nature 
with no parallel control group is a design with limitations, and the presence of 
spurious findings cannot be excluded. On the other hand, one may argue that ethical 
constraints associated with the superior performance characteristics of the hs-cTnT 
assay would have made it difficult to perform a prospective, adequately powered, 
controlled trial with similar research questions. Furthermore, our study represents a 
unique evaluation of true clinical practice that has quality assessment value and 
provides relevant information to the process of optimizing care of patients. We 
consider the sample sufficiently sized for the majority of the characteristics evaluated. 
However, some degree of interpretive prudence is warranted due to the unexpectedly 
low number of acute angiographies, which increases the potential for incidental 
observations in the classification of angiographic findings. The fact that a large 
proportion of primary NSTEMI admissions were older individuals who likely had co-
morbidities could explain the modest referral rate to angiography. Evidently, this 
characteristic also represents a restriction to both external and internal validity. 
Moreover, while the external validity of the study was enhanced by its reasonably 
large scale and realistic setting (114), it was conducted in one center which further 
limits generalizability. The internal validity was strengthened by exogenous exposure 
to the new assay, causing reduced propensity to interventional selection bias and the 
Hawthorne effect (115). This must be weighed against unmeasured properties 
potentially influencing the components unequally in the two periods. Most notably, 
these include unevaluated patient characteristics, natural temporal trends and bias 
being introduced by physicians being more cognizant of measuring cTn 
concentrations after the new assay and revised cut-off point had been implemented 
(116,117). 
Subjects receiving PCI for STEMI in a randomized trial were studied in a post 
hoc analysis in paper II. The nature of performing an analysis post hoc increases the 
probability of finding false relationships (118). At the same time, randomized trials 
 34 
often give researchers a unique opportunity to explore additional scientific questions 
beyond its primary hypothesis. In fact, it has been argued that investigators have an 
ethical and financial obligation to design and conduct trials in a fashion that 
maximizes its scientific capacity (119). A significant strength of the present study was 
the sample size, which was adequate for assessment of the predictive value of cTnI 
for clinical endpoints. Nevertheless, we appreciate that the total number of clinical 
events was modest and that extrapolating our findings to STEMI populations with 
higher event rates may not be appropriate. Indeed, randomized trials tend to include 
motivated patients with less co-morbidity, which imposes limitations to both external 
and internal validity. Our sample did not include NSTEMIs, there were fewer women 
than men, they were relatively young and the number of inferior infarctions was 
small, all of which restrict generalization even further. On the other hand, the 
described STEMI cohort reflects in a high degree a typical STEMI population 
encountered in daily clinical practice (120). If implementation into clinical practice is 
considered, one must also acknowledge the cTnI between-assay variation (121). In 
parallel, it remains evident that the strict inclusion and exclusion criteria facilitated a 
more streamlined and comparable hospital flow for all subjects, which, in turn, 
reduces the influence of background noise. This must be contrasted to numerous 
opposing threats to internal validity, including unexplored potential discrepancies in 
discharge medication, unknown effects of the experimental agent on the variables that 
were investigated and that the models for prediction of cardiac function did not 
account for the competing risk of death during follow-up. 
Individuals referred to the sleep laboratory for evaluation of possible OSA 
were examined in a single-center, cross-sectional study in paper III and IV. A single-
center study has limited external applicability and the cross-sectional design precludes 
interpretation of causal relations. We consider the size of the sample reasonably large. 
Nevertheless, due to uncertainties related to background noise and temporal relations 
between the independent predictors included in the models, it is still difficult to rule 
out the possibility of type 2 errors. A potential selection bias, reducing both external 
and internal validity, may have been introduced by participants made ineligible for 
inclusion if they had known OSA or if there was no serum sampled for biobank (due 
to technical difficulties or if they did not consent). It would also have been preferable 
to have a more balanced gender and age distribution. Moreover, since the subjects in 
the investigation were referred by a doctor based on a suspected sleeping disorder, we 
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cannot exclude that those who were found not to have OSA had a higher prevalence 
of undiagnosed medical conditions when contrasted to the general population. This 
may have influenced the results of our analyses and reduces the validity of our 
findings. 
 
Data collection and quality 
There are aspects of the data reported in paper I warranting consideration. First, we 
sought to limit information bias through implementing standardized procedures with 
few investigators involved in data collection. Additionally, a staff member not 
involved in the study validated all inputs during database building. Despite these 
efforts, we appreciate that the retrospective design, with researchers aware of the 
subjects exposed to the new assay, could have incited bias during data processing. 
Moreover, since classification of primary NSTEMI admissions was based on patients 
registered in the database upon discharge, it is possible that some admissions were 
omitted due to miscoding and that the extent of such errors was inconsistent across 
the two periods. Also, variations in biomarker sampling properties and differences 
between doctors performing the angiographies may have been present. For biomarker 
characteristics one should note that if a patient presented >24 hours after onset of 
symptoms, a rise and/or fall pattern was not absolutely required for a diagnosis of MI 
(17). As this was not considered in the study, it could be a source of error. 
Furthermore, if a time limit had been defined between the two measurements used for 
calculating dynamic changes, a higher proportion could have failed to qualify for the 
20% relative change criterion. Thus, some of the values may have had more hours 
between them than what would be appropriate. 
 The post hoc analysis of patients from a randomized trial in paper II has a 
significant strength in the sense that the data quality is quite robust. All data points 
had been prospectively defined and registered by an independent research 
organization. Moreover, independent central core laboratories were used for 
estimation of biochemical and cardiac function indices, while an independent 
committee adjudicated all clinical events. Nevertheless, the international and multi-
center feature imposes vulnerability to variations in both biomarker and LVEF 
sampling properties, as well as differences in how clinical events were assessed. Also, 
the analytical limitations of the utilized assay represent a possible source of inaccurate 
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cTnI data (122), while a potentially unbalanced distribution of missing values might 
have influenced the results for the cTnI variables explored. 
Paper III and IV evaluate cross-sectional data collected at only one time point 
susceptible to individual variability and random errors. Similar to the other studies, 
we cannot rule out the presence of pre-analytical differences during biomarker 
sampling. Since it was possible to perform multivariable regression analyses without 
undetectable cTn values and contrast the results of two independent methods, we 
consider the quantification of myocardial stress through the use of novel assays an 
advantage. Even so, we acknowledge the more limited reliability of the hs-cTnT assay 
in the lower concentration range. Moreover, the release kinetics of cTn molecules 
after myocardial stress may have caused the peak concentration to be reached later 
than the time of blood sampling, which could have induced a bias in cTn results. For 
the MRP-8/14 measurements, current knowledge of serum sampling in adults 
investigated for OSA is limited. We therefore consider the concomitant analyses of 
CRP beneficial, because it allowed us to assess the MRP-8/14 values in the context of 
a well-established marker of inflammation. The method used for estimation of MRP-
8/14 concentrations has been validated by the manufacturer with acceptable 
performance characteristics, and the analyses were performed by an experienced 
biomedical laboratory scientist blinded to study data. Nevertheless, we cannot exclude 
the presence of analytical errors, especially given limited experience with analyses of 
MRP-8/14 after storage at −80 °C (123). We tried to limit inconsistency by having a 
qualified sleeping disorder specialist not involved in the study scoring the sleep 
studies. Still, several potential sources of error remain, including differences in sleep 
quality, total recording time and favored body position between PG and PSG. 
Additionally, since the electroencephalogram from a PSG allows for exact 
determination of sleep time and respiratory arousals, it is possible that the calculated 
indices were underestimated in individuals examined with a PG. 
 
Statistical methods 
In paper I, the statistics were based on conventional methods; we performed a basic 
comparison of means, medians or proportions with appropriate significance tests. 
Since our statistical aim was to solely describe and compare pre-defined observations 
in two periods, the use of more advanced statistical methodologies were not deemed 
necessary.  
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Odds ratio, hazard ratio, C-statistics and IDI were used to assess prognostic 
information obtained from various cTnI variables presented in paper II. Multivariable 
logistic or Cox proportional hazards regression models are well-established methods 
used to explore if increasing biomarker levels signify a statistically significant 
increment in risk of an adverse outcome. However, the distributions of a biomarker in 
subjects with and without an adverse outcome often overlap. Increased attention has 
therefore recently been put on additional methods to assess whether a biomarker 
provides incremental information to overall prediction (57,124). The C-statistic is a 
rank-order statistic of a model that is interpreted through a pair of subjects with and 
without the outcome in question. It corresponds to the ROC-AUC (area under the 
receiving operating curve) of a test, which indicates the probability across the 
spectrum of cut-off values that a case will have a higher value than a non-case (111). 
In addition, the discrimination slope of a model can be calculated as the absolute 
difference in average predictions for those with and without the outcome (125). This 
difference in mean of predictions is a simple measure of how well subjects with and 
without an outcome are separated by a model, i.e. the discriminatory ability is 
quantified by a degree of separation from average predictions. The IDI is equivalent 
to the difference in discrimination slopes between two models, and it attempts to add 
to C-statistics by quantifying the change in separation of probabilities in cases and 
non-cases after addition of a new variable (112). The IDI measure is dependent on the 
rate of cases and is in some instances perceived as an abstract number to comprehend. 
Therefore, the relative IDI can be used as an alternative measure. This corresponds to 
how much predictive ability that has been added to the discrimination slope of the 
model that includes the variable, described as a percent value of the discrimination 
slope of the model without the variable (hence "relative") (113). Statistical methods 
are available to compare the C-statistics and the difference in discrimination slopes of 
two models (for example with and without a biomarker). On this background, 
estimations and tests of C-statistics and IDI measures were performed, and the results 
were presented along with hazard ratios or odds ratios in paper II. 
 Median regression was used to explore associations of variables presented in 
paper III and IV. Median regression is similar to linear regression. Both models 
describe the association(s) between a continuous dependent variable and one or more 
explanatory variables. Linear regression makes inference about the mean of the 
dependent variable, whereas median regression makes inference about the median. 
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Model-building techniques and general regression features, such as the ability to 
study interactions and non-linear effects, are available for median regression. Thus, 
due to the distributions of the variables in the dataset, it was considered preferable to 
perform the analyses of associations presented in paper III and IV by use of median 
regression. 
 
9.2 Discussion of results  
Cardiac troponin 
Since assays for detection of cTnI and cTnT were developed in the 1980s, the role of 
cTn in identifying necrosis following infarction of the myocardium has become firmly 
established (126,127). Several other applications of cTn measurements have since 
been discovered. Among the more recent are its uses in risk prediction when sampled 
after PCI and the assessment of subjects with other disorders or from the general 
population (71,128-136). In the present work, we evaluated characteristics of 
NSTEMI diagnostics after a hs-cTnT assay was implemented into clinical practice, 
and explored the value of different cTnI variables for prediction of clinical events and 
cardiac function following PCI for STEMI. Furthermore, we demonstrated the 
enhanced ability of novel cTn assays to identify myocardial stress in subjects 
investigated for possible OSA, and examined the associations between these 
biomarkers and variables of disordered breathing during sleep. Thus, the thesis entails 
a broad spectrum of findings adding new knowledge relevant to each of the 
abovementioned applications. 
Paper I describes several imperative changes in NSTEMI diagnostics that 
followed the introduction of a new hs-cTnT assay. The study illustrates a continuous 
improvement in the biomarker field, which, in turn, facilitates an ongoing innovation 
to the operational characteristics of an MI. We found that an increased number of 
NSTEMI admissions occurred in the last period. This was accompanied by more 
coronary angiographies being performed, and a higher proportion of these showed no 
signs of CAD. Moreover, significant dynamic cTnT changes were somewhat less 
frequent. The increase in NSTEMI diagnoses associated with the use of hs-cTnT and 
a lower cut-off point is supported by findings from other types of populations 
(21,22,137). However, by evaluating diagnostics in a large and more unselected group 
over two one-year periods, the present study is distinctive in that it scrutinizes the 
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increase in primary NSTEMI admissions following the introduction of this assay into 
real world hospital practice. Although it was to be predicted that the use of a lower 
cut-off point would result in more NSTEMIs, the extent of change was difficult to 
foresee, especially since the difference in assay calibration would likely also 
contribute to the increase. This latter additive component implies that the high-
sensitivity assay uniformly shows higher values in the lower concentration range, 
resulting in more subjects qualifying for MI diagnosis at a certain cut-off level (99). 
Thus, if the same cut-off concentration had been applied in the two periods, it is 
probable that this positive bias would still have led to more patients being diagnosed 
with NSTEMI in the period when hs-cTnT was used (138). The exact fraction of the 
increment observed in our study potentially attributable to this assay disparity remains 
unknown. In any event, if the hospital were to lower the cut-off point further to the 
international guideline-recommended 99th percentile concentration of the hs-cTnT 
assay, our findings support that the intensified detection of potential ischemic 
myocardial necrosis would likely result in an even higher number of patients being 
diagnosed with NSTEMI (23). 
The study also sheds light on other aspects by examining angiography and 
biomarker characteristics. In association with the greater number of individuals 
clinicians had to evaluate due to elevated cTnT levels, it was a concern in the medical 
community that the high-sensitivity assay would result in more patients being 
misdiagnosed. Therefore, since additional properties of these admissions could 
elucidate features indicative of deficient diagnostic accuracy in the last period, they 
were of considerable interest. Through our assessment of angiographies, we 
demonstrated a larger proportion without signs of CAD, but noted that the number 
was small and that these patients may have had a “Myocardial Infarction with Normal 
Coronary Arteries” (139). Irrespective of this uncertainty, many would uphold that the 
most noteworthy finding was that the majority in both periods actually was consistent 
with pathological changes. However, in further reviewing biomarker characteristics, 
we also identified a higher number of patients with smaller dynamic cTnT changes in 
the last period. This may imply that more patients lacked a significant rise and/or fall 
pattern, which, according to the guidelines, was a prerequisite for the diagnosis (17). 
The extent of dynamic change required is an ongoing debate (140-143). Also, since it 
may improve sensitivity and specificity, some have promoted the use of absolute 
instead of relative changes (144). We chose a relative concentration change of 20% in 
 40 
our study, consistent with the level used in some previous studies (22,145). Others 
have promoted the use of a higher differential, especially at low baseline cTn levels 
(146). When calculating relative changes, these studies applied serial measurements 
taken a few hours after admission. We used the highest and lowest registered values 
on each admission, without considering the timeline between measurements. No 
consensus currently exists with regard to the level of dynamic change representing 
ischemic myocardial necrosis with certainty. While the abovementioned findings may 
support that a higher number of patients were misdiagnosed in the last period, the use 
of the high-sensitivity assay may still be preferable since a larger number of patients 
were identified and subsequently referred to a higher level of care. This, in turn, 
presumably led to reduced morbidity and mortality (137). Moreover, our investigation 
suggests that more patients will have to be considered for potentially having increased 
cTnT levels due to other etiologies than MI. Consequently, the results from the study 
underscore the importance of meticulous attention and coherence to the diagnostic 
criteria for MI during assessment of patients, to minimize the risk of misdiagnoses 
(14). 
 In paper II, an evaluation of the prognostic value of cTnI is presented. The 
study strongly supports the perception that cTnI is a clinically useful risk stratification 
tool. In exploring the relationship between multiple cTnI measurements and 
comprehensive three-month outcome assessments in contemporary PCI-treated 
STEMI patients, it is the largest of its kind. Previous work has established that infarct 
size is a main determinant of future risk following MI (33,147), and shown that 
single-point or derived measures of cTn are easy available surrogates for infarct size 
(148-151). Thus, we designed various models to determine the prognostic value of 
different cTnI variables in prediction of adverse clinical events and follow-up cardiac 
dysfunction. The results do validate other investigations that have explored the 
association between cTn and clinical outcomes or left ventricular indices (149,151-
156). At the same time, the study adds to previous findings through its extensive 
evaluation of multitudinous cTnI variables. Moreover, it demonstrates the significant 
incremental discriminative value of the biomarker and examines the relationship 
between index event cTnI values and NT-proBNP concentrations sampled at three 
months. NT-proBNP is currently being tested as a tool in biomarker-guided treatment 
of chronic heart failure in a prospective, large, multi-center, randomized controlled 
trial (GUIDE-IT), with a chosen threshold of 118 pmol/L. Our analyses indicate that 
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cTnI significantly improves discrimination of follow-up NT-proBNP concentrations 
above this threshold value. The present work therefore represents provisional 
evidence for a potential future application in identifying at-risk individuals possibly 
qualifying for biomarker-guided heart failure treatment following STEMI. 
For the purpose of risk prediction in STEMI patients treated with primary PCI, 
the overall pattern of the results presented in paper II may be interpreted to support 
the superiority of single-point measurements from 16-24 hours and beyond compared 
to earlier time points. This is in agreement with previous publications that have 
reported comparable findings using other assays (149,152). The difference among the 
derived variables were less distinct, but the results for AUC were consistently better 
than peak in all models. The time curve of cTnI concentrations after reperfusion is 
characterized by a peak at ≤12 hours as the cytosolic pool is rapidly washed out, 
followed by a slowly abating plateau as the structural pool is gradually liberated 
(129,149). It is plausible that variables reflecting degradation of the structural pool are 
more closely correlated to permanent myocardial injury. Thus, measures more 
influenced by cTnI from the cytosolic pool may perform poorer in predicting 
outcomes. Since CIs were broad and no direct statistical comparisons between cTnI 
variables were made, this explanation remains speculative and not specifically tested 
in our investigation. Many would however contend that the clinical applicability is 
ultimately determined by the accuracy of the prognostic information, the time at 
which this information is available and how feasible it is to obtain. The results from 
the present analyses are therefore also of great value in this respect, since they suggest 
that the majority of the explored cTnI variables can be applied to significantly 
enhance risk stratification of these patients. As such, to advance more informed 
decisions regarding patient management to the initial phase of hospital admission, 
earlier single-points may be preferred by some clinicians. 
In recent years, following several investigations that have determined the 
significant predictive value of cTn in numerous non-ischemic acute and chronic 
disorders, its role in prognostic assessment in other diseases beyond MI has evolved 
substantially (71,134,135). Furthermore, through the use of refined assays that 
facilitate recognition of miniscule myocardial injuries previously undetectable with 
earlier generation assays, it has been shown that cTn can be identified in a much 
larger proportion of the general population and is independently associated with the 
risk of adverse outcomes in such subjects (130-132). As a consequence of this 
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enhanced ability to delineate myocardial status in more healthy individuals, the 
potential utility in other areas has become a developing field of intense research. In 
paper III, an accession to this innovative application is reported through analyses of 
circulating cTnI and cTnT in individuals investigated for possible OSA. The study 
examines the presence of myocardial stress through utilization of S-cTnI and hs-cTnT 
assays and explores the associations to variables of disordered breathing during sleep. 
It is to the best of our knowledge the first description of quantified cTn concentrations 
in 100% of subjects evaluated for the disorder.  
OSA is associated with several phenotypical risk indicators previously linked 
to cTn, such as heart failure, BMI, CAD and diabetes (3,4,43,157-159). Thus, since 
other concomitant factors likely contributed to the degree of myocardial stress 
present, it was unsurprising that our findings were consistent with OSA patients 
having a different distribution of cTn. Nevertheless, there are several additional 
mechanisms discussed in literature conceivably making the myocardium more 
vulnerable to repetitive minor stress in OSA. These include hypoxia, increased left 
ventricular transmural pressure, pulmonary hypertension, sympathetic activation, sub-
clinical arrhythmia, blood pressure surges, tachycardia, oxidative stress, 
inflammation, endothelial dysfunction, platelet activation and hypercoagulability (49). 
Still, an independent association between severity of OSA and increasing cTn levels 
had not been demonstrated in comparable study samples when our investigation was 
initiated (160,161), and none had reported concurrent cTnI and cTnT measurements. 
Importantly, the quantification of cTn molecules in these previous studies had been 
hampered by assay limitations at lower concentration levels. On this background, to 
allow for a more exhaustive and definite evaluation of a potential association with 
worsening OSA, a better measure of myocardial stress was desirable. Through the 
increased sensitivity and precision of the S-cTnI assay, we were able to overcome this 
impediment. The assessment was further reinforced by the hs-cTnT analyses, albeit 
somewhat less definite, since a higher proportion of values were below the assay´s 
LoQ. Despite the use of innovative assays, which facilitated a more rigorous 
estimation of myocardial status in all participants, our investigation was consistent 
with earlier studies in not demonstrating an independent relationship between AHI 
and cTn levels (160,161). 
Provided that the abovementioned mechanisms were operational in our study 
sample and are truly causative of significant myocardial stress in OSA, it is evident 
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that they were not adequately reflected by AHI if one assumes that other predictors 
were appropriately accounted for in the multivariable analyses. Hypoxic exposure is a 
component where such a concern is reasonable; potentially being a key determinant of 
myocardial cell stress not directly proportional with disordered breathing per se. The 
duration of the apneas and hypopneas may also be of importance and this information 
is not provided by the AHI measure. Alternatively, upholding that it is a true 
association between the two variables, it may have been inconsistently masked by 
unmeasured confounders or too weak to be identified. Nevertheless, recently 
published studies have reported conflicting evidence for the potential link between 
increasing AHI and myocardial stress; some have demonstrated an independent 
relationship in multivariable models (162,163), while another did not find a 
significant association after adjustment for confounding factors (164). Moreover, 
when contrasted to ODI and nadir oxygen saturation, stronger associations of average 
oxygen saturation and time below 90% oxygen saturation to cTn were found in our 
study. This may suggest that chronic rather than intermittent hypoxia is more closely 
related to myocardial cell stress. Interestingly, a possible protective effect through 
ischemic preconditioning of the myocardium in OSA patients with an established MI 
has been posited in a recent report (165). The theory is supported by experimental 
animal studies (166). Intermittent phases of hypoxia or other unknown effects of 
disordered breathing have been hypothesised as stimulators of collateral blood flow 
through angiogenic mediators, possibly facilitating improved blood flow and 
myocardial salvage (167,168). Studies exploring cTn in relation to possible 
myocardial stress in other transient settings such as exercise stress testing have also 
revealed conflicting results (68,169-171). It is conceivable that related mechanisms 
may have been operative in our study sample, thus precluding a pattern of increasing 
cTn levels in patients with more severe AHI. However, this interpretation must be 
appraised with great caution, as the degree of confounding was not sufficiently 
investigated. Nevertheless, the paradigms described support a more thorough 
exploration of different categories of hypoxia and its subsequent effects in the future. 
Similar to previous data from other types of populations, we observed 
discordance between measured cTnI and cTnT concentrations in our study of 
individuals investigated for possible OSA (133,169,172). The same finding has also 
recently been reported in an analysis of subjects examined for possible OSA from the 
general population (162). Different release kinetics due to a smaller molecular size of 
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cTnI versus cTnT, together with unequal post-translational modification, could be 
contributing factors to disharmonious cTn concentrations at a given time point 
(70,173). Furthermore, the disparate properties of the assays may in itself explain the 
discordance observed. However, there may be subtle differences in etiologies 
underpinning liberation of cTnI versus cTnT from the myocyte and clearance 
mechanisms from the circulation (133). Hence, one cannot exclude that the variation 
at least in part reflects true biological heterogeneity. We also observed that more 
patients measured above the 99th percentile with the S-cTnI assay. This finding is in 
agreement with current evidence, suggesting that cut-off points differ depending on 
the characteristics of the group examined to obtain them (107,174,175). Nonetheless, 
for both assays applied in our study, it was documented that most individuals had cTn 
levels within the normal reference range. 
 
Myeloid-related protein-8/14 and C-reactive protein 
Paper IV reports a shift in focus from myocardial stress to inflammation. 
Inflammation is a component implicated as a possible causal pathway of CVD in 
OSA. While previous work has demonstrated that children with OSA have elevated 
levels of MRP-8/14 (176,177), data from adults is lacking. Conversely, CRP has been 
studied quite extensively in adults with OSA, but with conflicting results (178-181). 
The present investigation is therefore of interest as it evaluates, in a reasonably large 
sample of subjects investigated for possible OSA, the associations between variables 
of disordered breathing during sleep and two disparate indicators of inflammatory 
activity. In addition, it provides new knowledge by probing potential interactions 
between variables of disordered breathing during sleep and BMI on inflammation. 
Recurrent bouts of hypoxia, arousal and increased negative intrathoracic 
pressure represent a conglomerate of noxious stimuli with detrimental effects in 
patients with OSA (5,44,49). Thus, it is theoretically plausible that the disorder may 
promote immune system activation and increased levels of inflammatory biomarkers. 
In agreement with this conception, AHI was observed to be associated with both 
MRP-8/14 and CRP in our baseline models, and it remained a predictor of CRP also 
after adjustment for BMI. However, the association between AHI and biomarker 
concentrations did not remain statistically significant in final models, which included 
additional components previously linked to inflammation (182-184). Different study 
designs and sample sizes may have contributed to the diverse results of prior studies 
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exploring inflammation in OSA (178-181). In particular, the role of potential 
confounders has proven evasive, since the specific causal pathways potentially linking 
apneas and hypopneas, inflammation, other components and CVD remain complex 
and not fully elucidated. The results from our cross-sectional investigation must 
therefore be interpreted with great caution, as we cannot be certain that the factors 
included for adjustment were the appropriate selection for this specific setting. 
Moreover, intermittent hypoxia is currently believed to be the main activator of 
inflammatory pathways in OSA (5,44,49). Hence, with this constituent not directly 
proportional to the number of apneas and hypopneas per se, our lack of association 
may be due to inaccuracy of the AHI variable in reflecting intermittent hypoxic 
exposure in each of the subjects. Furthermore, given that the AHI variable does not 
reflect the duration of each apnea and hypopnea, we cannot exclude the possibility 
that inflammatory activity is more dependent on the length than number of events. 
 The associations of various metrics of oxygen saturation with inflammatory 
biomarker levels differed between MRP-8/14 and CRP. In the final models, average 
oxygen saturation was an independent predictor of MRP-8/14 levels, while ODI was a 
predictor of CRP. These findings support that MRP-8/14 and CRP have different 
pathways of expression and/or breakdown patterns, which is further endorsed by their 
modest correlation. Nuclear factor kappa-B mediated pathways have been proposed as 
possible triggers of inflammation in patients with OSA (44). MRP-8/14 is secreted 
mainly by neutrophils and monocytes (185), but the underlying mechanisms remain 
less understood. Traditionally, CRP has been regarded synthesized by hepatocytes in 
response to factors produced by adipose tissue and inflammatory cells (84,86-90). 
Intriguingly, extra-hepatic tissues such as smooth muscle and fat have also been 
demonstrated to express CRP (91,93). In light of these observations, it is interesting 
that we found a quantitative interaction between BMI and several variables of 
disordered breathing during sleep on both biomarkers. A recent publication has 
described a possible interaction between obesity and OSA on interleukin-6 and CRP 
(178). Thus, these findings support the hypothesis that adipose tissue may be involved 
in CRP production, but one cannot exclude that it is an indirect effect promoting 
increased synthesis from hepatocytes. Why a similar phenomenon was observed for 
MRP-8/14 is not known. Nonetheless, the results from our analyses support that 
individuals with higher BMI demonstrated an amplified inflammatory response in 
association with worsening levels of several of the variables of disordered breathing 
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during sleep. Thus, patients with OSA may have had activated inflammatory 
pathways inconsistently masked by unmeasured confounders or too diminutive to be 
significant in this study sample.
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10. CONCLUSION 
 
The aim of this thesis was to provide further insight into novel aspects of circulating 
biomarkers associated with CVD, with an emphasis on MI and OSA.  
 
• The thesis indicates that the introduction of a hs-cTnT assay enhanced 
NSTEMI diagnostics, while in parallel implying that more patients will have 
to be considered for potentially having increased cTnT levels due to other 
etiologies than MI. 
 
• The dissertation demonstrates that a single measurement of cTnI after PCI 
provides incremental information to prediction of clinical events and cardiac 
function following STEMI.  
 
• Through quantification of myocardial stress in all individuals investigated for 
possible OSA, the thesis confirms that the improved performance 
characteristics of S-cTnI and hs-cTnT are broadening potential applications of 
cTn assays.  
 
• The observed interaction between a higher BMI and several variables of 
disordered breathing during sleep may indicate activated inflammatory 
pathways inconsistently masked by unmeasured confounders or too moderate 
to be significant in this study sample. Still, the dissertation suggests that the 
future clinical utility of the investigated biomarkers appears limited for the 
diagnostic evaluation of possible OSA. 
 
The findings expand our knowledge of these biomarkers and contribute to determine 
their future role in patient care.
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11. IMPLICATIONS AND FUTURE PERSPECTIVES 
 
Measurements of circulating biomarkers are increasingly being implemented as 
essential tools in the detection of disease, assessment of prognosis and monitoring of 
responses to interventions. The high rate of new discoveries and refinements in assay 
technology are accompanied by a continuous search for innovative clinical 
applications. This thesis has attempted to provide clinically relevant insights into 
several aspects of circulating biomarkers associated with CVD. First, it has illustrated 
salient issues related to NSTEMI diagnostics following the use of a high-sensitivity 
assay, which are highly relevant to the assessment and care of patients in current 
hospital practice. Our results suggest that the introduction of more sensitive cTn 
assays increases the demands on the physician in the diagnostic process. Thus, 
meticulous attention to the criteria for MI, as well as sound clinical judgement, has 
become even more important. Second, the dissertation demonstrates that a single 
measurement of cTnI after PCI for STEMI provides significant incremental 
information to risk prediction. We consider the findings of this study of great value to 
doctors involved in prognostication and treatment of such patients today. Potentially, 
cTn may also be used to aid in selecting individuals to be considered for inclusion in 
clinical trials aimed to improve outcomes in similar populations (a principle termed 
“trial population enrichment”). Third, through estimation of myocardial stress in all 
individuals who participated in a study where they were investigated for possible 
OSA, the thesis has exemplified that the enhanced performance characteristics of S-
cTnI and hs-cTnT are broadening the potential applications of cTn assays. Although 
the future clinical utility of all the biomarkers explored appears limited for the 
diagnostic assessment of the disorder, our comprehension of possible 
pathophysiological mechanisms have been improved through the contemporary 
descriptions of myocardial stress and inflammation in the sample studied. 
An ideal biomarker should aid the clinician in diagnosis, prognosis and 
treatment. It should be readily available and adequately tested, have an established 
reference value compared to a “gold standard”, have a known sensitivity and 
specificity level, a rapid turnaround time and not be costly (186). Our work has 
provided results that expand our knowledge base and help to define the future 
potential applications of the biomarkers investigated. Recognizing that the presented 
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findings are one piece of a larger puzzle, there are additional aspects related to our 
research questions that will be important to investigate in subsequent studies. In our 
exploration of hospital admissions, we demonstrated that the introduction of a refined 
assay and a lower cut-off point was associated with several changes relevant to 
NSTEMI diagnostics. A while after the paper was published and following updated 
recommendations from a national expert group, our hospital along with several others 
in Norway further reduced the cut-off point for MI to the 99th percentile concentration 
of the hs-cTnT assay. To maximize the quality of care offered to patients, the 
implications of such a change in real world hospital practice will be important to 
examine in future studies. Our findings in STEMI patients, while novel, fit very well 
with previous analyses. The results are biologically plausible and consistent with 
current mechanistic insights. Thus, prospective trials in more unselected populations, 
validating the use of cTn for prediction of clinical events and determining the exact 
implementation strategy to risk scoring tools, are needed before introducing the 
present risk prediction concept on a broader scale. Moreover, we envision that testing 
a cTnI biomarker-guided approach, for purposes of implementing an aggressive anti-
remodeling strategy before discharge in patients at increased risk of heart failure at 
three months, could prove beneficial. The relative value of the predictive information 
provided by cTnI, when considered with additional outcome-related biomarkers, also 
remains uncertain. For example, it will be important to simultaneously assess cTnI 
with markers such as angiographic flow and blush, NT-proBNP, ST-segment 
recovery and reperfusion ventricular arrhythmia “bursts”. Additionally, our study of 
individuals investigated for possible OSA has confirmed that the development of 
novel assays has expanded the potential area for use of cTn measurements in the field 
of medicine. However, the value of stratifying subjects based on cTn values within 
the normal reference range will vary between populations. Specific studies addressing 
these differences will be essential to better define the clinical utility. Evidently, the 
cross-sectional design of the study makes it challenging to establish causal 
relationships and conclusions concerning pathophysiological pathways in OSA. 
Therefore, one cannot rule out that mechanisms entailing myocardial stress or 
inflammation are operative and contribute to an increased risk of CVD events. In 
view of two recent publications demonstrating an independent relationship between 
OSA and myocardial stress (162,163), specific mechanistic studies of 
pathophysiological pathways and the potential protectiveness of ischemic 
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preconditioning would be important to increase our understanding (187). Similarly, in 
light of meta-analyses indicating that inflammatory biomarkers are higher in OSA and 
may partially be suppressed by CPAP treatment (50,188), it appears additional studies 
are needed before drawing definite conclusions. The clinical ramifications of the 
potential interaction with BMI on inflammation also remain unknown and 
clarification of this possible phenomenon would be helpful. Indisputably, meticulous 
attention to study design, size, participant selection and the methods used to evaluate 
parameters will be essential in upcoming trials to clearly establish whether noxious 
stimuli resulting from disordered breathing during sleep are truly causative of 
myocardial stress and inflammatory activity in patients with OSA.
 51 
12. REFERENCES 
 
 
1. World Health Organization. Global status report on noncommunicable 
diseases 2010. Geneva: WHO Press, 2011. 
2. Maton A, Hopkins J, McLaughlin CW, et al. Human Biology and Health. 
Englewood Cliffs, NJ: Prentice Hall, 1993. 
3. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive 
sleep apnea and incident coronary heart disease and heart failure: the sleep 
heart health study. Circulation 2010; 122:352-60. 
4. Shah NA, Yaggi HK, Concato J, Mohsenin V. Obstructive sleep apnea as a 
risk factor for coronary events or cardiovascular death. Sleep Breath 2010; 
14:131-6. 
5. Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular 
consequences. Lancet 2009; 373:82-93. 
6. World Health Organization. Global atlas on cardiovascular disease prevention 
and control. Geneva: WHO Press, 2011. 
7. Herrick JB. Landmark article (JAMA 1912). Clinical features of sudden 
obstruction of the coronary arteries. By James B. Herrick. JAMA 1983; 
250:1757-65. 
8. White HD, Chew DP. Acute myocardial infarction. Lancet 2008; 372:570-84. 
9. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. 
Nature 1993; 362:801-9. 
10. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 
2005; 111:3481-8. 
11. Insull W Jr. The pathology of atherosclerosis: plaque development and plaque 
responses to medical treatment. Am J Med 2009; 122:S3-S14. 
12. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 
340:115-26. 
13. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of 
coronary artery disease and the acute coronary syndromes (1). N Engl J Med 
1992; 326:242-50. 
14. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of 
myocardial infarction. J Am Coll Cardiol 2012; 60:1581-98. 
15. Atar D. [How to diagnose a heart attack in 2012?]. Tidsskr Nor Laegeforen 
2012; 132:265-6. 
16. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction 
redefined--a consensus document of The Joint European Society of 
Cardiology/American College of Cardiology Committee for the redefinition of 
myocardial infarction. J Am Coll Cardiol 2000; 36:959-69. 
17. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial 
infarction. Eur Heart J 2007; 28:2525-38. 
18. Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac 
troponin measurement in acute cardiac care. Eur Heart J 2010; 31:2197-204. 
19. Apple FS, Wu AH, Jaffe AS. European Society of Cardiology and American 
College of Cardiology guidelines for redefinition of myocardial infarction: 
how to use existing assays clinically and for clinical trials. Am Heart J 2002; 
144:981-6. 
20. Aakre KM, Landaas S, Hagve TA. [Use of troponin analysis in Norwegian 
hospitals]. Tidsskr Nor Laegeforen 2010; 130:278-81. 
 52 
21. Christ M, Popp S, Pohlmann H, et al. Implementation of high sensitivity 
cardiac troponin T measurement in the emergency department. Am J Med 
2010; 123:1134-42. 
22. Giannitsis E, Becker M, Kurz K, Hess G, Zdunek D, Katus HA. High-
sensitivity cardiac troponin T for early prediction of evolving non-ST-segment 
elevation myocardial infarction in patients with suspected acute coronary 
syndrome and negative troponin results on admission. Clin Chem 2010; 
56:642-50. 
23. Mills NL, Lee KK, McAllister DA, et al. Implications of lowering threshold of 
plasma troponin concentration in diagnosis of myocardial infarction: cohort 
study. BMJ 2012; 344:e1533. 
24. Christ M, Bertsch T, Popp S, Bahrmann P, Heppner HJ, Muller C. High-
sensitivity troponin assays in the evaluation of patients with acute chest pain 
in the emergency department. Clin Chem Lab Med 2011; 49:1955-63. 
25. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-
elevation myocardial infarction: A convenient, bedside, clinical score for risk 
assessment at presentation: An intravenous nPA for treatment of infarcting 
myocardium early II trial substudy. Circulation 2000; 102:2031-7. 
26. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality 
in the global registry of acute coronary events. Arch Intern Med 2003; 
163:2345-53. 
27. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable 
angina/non-ST elevation MI: A method for prognostication and therapeutic 
decision making. JAMA 2000; 284:835-42. 
28. Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and 
myocardial infarction in the six months after presentation with acute coronary 
syndrome: prospective multinational observational study (GRACE). BMJ 
2006; 333:1091. 
29. Amin ST, Morrow DA, Braunwald E, et al. Dynamic TIMI risk score for 
STEMI. J Am Heart Assoc 2013; 2:e003269. 
30. De Luca G, Suryapranata H, van 't Hof AW, et al. Prognostic assessment of 
patients with acute myocardial infarction treated with primary angioplasty: 
implications for early discharge. Circulation 2004; 109:2737-43. 
31. Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary 
percutaneous coronary intervention for acute myocardial infarction: the 
CADILLAC risk score. J Am Coll Cardiol 2005; 45:1397-405. 
32. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all 
forms of acute coronary syndrome: estimating the risk of 6-month 
postdischarge death in an international registry. JAMA 2004; 291:2727-33. 
33. Wu E, Ortiz JT, Tejedor P, et al. Infarct size by contrast enhanced cardiac 
magnetic resonance is a stronger predictor of outcomes than left ventricular 
ejection fraction or end-systolic volume index: prospective cohort study. Heart 
2008; 94:730-6. 
34. Burns RJ, Gibbons RJ, Yi Q, et al. The relationships of left ventricular 
ejection fraction, end-systolic volume index and infarct size to six-month 
mortality after hospital discharge following myocardial infarction treated by 
thrombolysis. J Am Coll Cardiol 2002; 39:30-6. 
35. Osler W. The Principles and Practice of Medicine. 8th edition. New York, 
NY: Appleton, 1918. 
 53 
36. Burwell CS, Robin ED, Whaley RD, Bickelmann AG. Extreme obesity 
associated with alveolar hypoventilation; a Pickwickian syndrome. Am J Med 
1956; 21:811-8. 
37. Gastaut H, Tassinari C, Duron B. Étude polygraphique des manifestations 
épisodiques (hypniques et respiratoires), diurnes et nocturnes, du syndrome de 
Pickwick. Rev Neurol 1965; 112:568-79. 
38. Guilleminault C, Tilkian A, Dement WC. The sleep apnea syndromes. Annu 
Rev Med 1976; 27:465-484. 
39. American Academy of Sleep Medicine. International classification of sleep 
disorders. 3rd edition. Darien, IL: American Academy of Sleep Medicine, 
2014. 
40. Duran J, Esnaola S, Rubio R, Iztueta A. Obstructive sleep apnea-hypopnea 
and related clinical features in a population-based sample of subjects aged 30 
to 70 yr. Am J Respir Crit Care Med 2001; 163:685-9. 
41. Hrubos-Strom H, Randby A, Namtvedt SK, et al. A Norwegian population-
based study on the risk and prevalence of obstructive sleep apnea. The 
Akershus Sleep Apnea Project (ASAP). J Sleep Res 2011; 20:162-70. 
42. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased 
prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013; 
177:1006-14. 
43. Young T, Shahar E, Nieto FJ, et al. Predictors of sleep-disordered breathing in 
community-dwelling adults: the Sleep Heart Health Study. Arch Intern Med 
2002; 162:893-900. 
44. Kohler M, Stradling JR. Mechanisms of vascular damage in obstructive sleep 
apnea. Nat Rev Cardiol 2010; 7:677-85. 
45. Eckert DJ, Malhotra A. Pathophysiology of adult obstructive sleep apnea. Proc 
Am Thorac Soc 2008; 5:144-53. 
46. Ryan CM, Bradley TD. Pathogenesis of obstructive sleep apnea. J Appl 
Physiol 2005; 99:2440-50. 
47. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of 
moderate weight change and sleep-disordered breathing. JAMA 2000; 
284:3015-21. 
48. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: 
a population health perspective. Am J Respir Crit Care Med 2002; 165:1217-
39. 
49. Kasai T, Floras JS, Bradley TD. Sleep apnea and cardiovascular disease: a 
bidirectional relationship. Circulation 2012; 126:1495-510. 
50. Xie X, Pan L, Ren D, Du C, Guo Y. Effects of continuous positive airway 
pressure therapy on systemic inflammation in obstructive sleep apnea: a meta-
analysis. Sleep Med 2013; 14:1139-50. 
51. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects 
of continuous positive airway pressure on early signs of atherosclerosis in 
obstructive sleep apnea. Am J Respir Crit Care Med 2007; 176:706-12. 
52. Haentjens P, Van Meerhaeghe A, Moscariello A, et al. The impact of 
continuous positive airway pressure on blood pressure in patients with 
obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-
controlled randomized trials. Arch Intern Med 2007; 167:757-64. 
53. Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous 
positive airway pressure in patients with heart failure and obstructive sleep 
apnea. N Engl J Med 2003; 348:1233-41. 
 54 
54. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular 
outcomes in men with obstructive sleep apnoea-hypopnoea with or without 
treatment with continuous positive airway pressure: an observational study. 
Lancet 2005; 365:1046-53. 
55. Buchner NJ, Sanner BM, Borgel J, Rump LC. Continuous positive airway 
pressure treatment of mild to moderate obstructive sleep apnea reduces 
cardiovascular risk. Am J Respir Crit Care Med 2007; 176:1274-80. 
56. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: 
preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 
69:89-95. 
57. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and 
practical considerations. Circulation 2006; 113:2335-62. 
58. Jarolim P. Overview of cardiac markers in heart disease. Clin Lab Med 2014; 
34:1-14. 
59. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel 
cardiovascular biomarkers. Circulation 2007; 115:949-52. 
60. Braunwald E. The rise of cardiovascular medicine. Eur Heart J 2012; 33:838-
46. 
61. Mathers CD, Loncar D. Projections of global mortality and burden of disease 
from 2002 to 2030. PLoS Med 2006; 3:e442. 
62. Greaser ML, Gergely J. Reconstitution of troponin activity from three protein 
components. J Biol Chem 1971; 246:4226-33. 
63. Filatov VL, Katrukha AG, Bulargina TV, Gusev NB. Troponin: structure, 
properties, and mechanism of functioning. Biochemistry (Mosc) 1999; 
64:969-85. 
64. Takeda S, Yamashita A, Maeda K, Maéda Y. Structure of the core domain of 
human cardiac troponin in the Ca(2+)-saturated form. Nature 2003; 424:35-41. 
65. Mohammed AA, Januzzi JL Jr. Clinical applications of highly sensitive 
troponin assays. Cardiol Rev 2010; 18:12-9. 
66. Fishbein MC, Wang T, Matijasevic M, Hong L, Apple FS. Myocardial tissue 
troponins T and I. An immunohistochemical study in experimental models of 
myocardial ischemia. Cardiovasc Pathol 2003; 12:65-71. 
67. Giannitsis E, Roth HJ, Leithauser RM, Scherhag J, Beneke R, Katus HA. New 
highly sensitivity assay used to measure cardiac troponin T concentration 
changes during a continuous 216-km marathon. Clin Chem 2009; 55:590-2. 
68. Sabatine MS, Morrow DA, de Lemos JA, Jarolim P, Braunwald E. Detection 
of acute changes in circulating troponin in the setting of transient stress test-
induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 
35. Eur Heart J 2009; 30:162-9. 
69. White HD. Pathobiology of troponin elevations: do elevations occur with 
myocardial ischemia as well as necrosis? J Am Coll Cardiol 2011; 57:2406-8. 
70. Agewall S, Giannitsis E, Jernberg T, Katus H. Troponin elevation in coronary 
vs. non-coronary disease. Eur Heart J 2011; 32:404-11. 
71. Giannitsis E, Katus HA. Cardiac troponin level elevations not related to acute 
coronary syndromes. Nat Rev Cardiol 2013; 10:623-34. 
72. Frosch M, Strey A, Vogl T, et al. Myeloid-related proteins 8 and 14 are 
specifically secreted during interaction of phagocytes and activated 
endothelium and are useful markers for monitoring disease activity in 
pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 
43:628-37. 
 55 
73. Murao S. Two calcium-binding proteins, MRP8 and MRP14: a protein 
complex associated with neutrophil and monocyte activation. Acta Histochem 
Cytochem 1994; 27:107-116. 
74. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory 
axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 
1999; 97:889-901. 
75. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR. S100A8 and S100A9 
mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for 
advanced glycation end products. Circ Res 2008; 102:1239-46. 
76. Croce K, Gao H, Wang Y, et al. Myeloid-related protein-8/14 is critical for the 
biological response to vascular injury. Circulation 2009; 120:427-36. 
77. Malemud CJ. Myeloid-related protein activity in rheumatoid arthritis. Int J 
Inflam 2011; 2011:580295. 
78. Altwegg LA, Neidhart M, Hersberger M, et al. Myeloid-related protein 8/14 
complex is released by monocytes and granulocytes at the site of coronary 
occlusion: a novel, early, and sensitive marker of acute coronary syndromes. 
Eur Heart J 2007; 28:941-8. 
79. Healy AM, Pickard MD, Pradhan AD, et al. Platelet expression profiling and 
clinical validation of myeloid-related protein-14 as a novel determinant of 
cardiovascular events. Circulation 2006; 113:2278-84. 
80. Morrow DA, Wang Y, Croce K, et al. Myeloid-related protein 8/14 and the 
risk of cardiovascular death or myocardial infarction after an acute coronary 
syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: 
Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart 
J 2008; 155:49-55. 
81. Schaub N, Reichlin T, Meune C, et al. Markers of plaque instability in the 
early diagnosis and risk stratification of acute myocardial infarction. Clin 
Chem 2012; 58:246-56. 
82. Vora AN, Bonaca MP, Ruff CT, et al. Diagnostic evaluation of the MRP-8/14 
for the emergency assessment of chest pain. J Thromb Thrombolysis 2012; 
34:229-34. 
83. Chen YS, Yan W, Geczy CL, Brown MA, Thomas R. Serum levels of soluble 
receptor for advanced glycation end products and of S100 proteins are 
associated with inflammatory, autoantibody, and classical risk markers of joint 
and vascular damage in rheumatoid arthritis. Arthritis Res Ther 2009; 11:R39. 
84. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 
2003; 111:1805-12. 
85. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-
reactive protein and its complex with phosphocholine. Structure 1999; 7:169-
77. 
86. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: 
an update. Clin Endocrinol (Oxf) 2006; 64:355-65. 
87. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin 
Immunol 2005; 115:911-9. 
88. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of 
white adipose tissue. Br J Nutr 2004; 92:347-55. 
89. Trayhurn P, Wood IS. Signalling role of adipose tissue: adipokines and 
inflammation in obesity. Biochem Soc Trans 2005; 33:1078-81. 
90. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the 
release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes 
 56 
from visceral and subcutaneous abdominal adipose tissues of obese humans. 
Endocrinology 2004; 145:2273-82. 
91. Calabro P, Chang DW, Willerson JT, Yeh ET. Release of C-reactive protein in 
response to inflammatory cytokines by human adipocytes: linking obesity to 
vascular inflammation. J Am Coll Cardiol 2005; 46:1112-3. 
92. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-
reactive protein production by human coronary artery smooth muscle cells. 
Circulation 2003; 108:1930-2. 
93. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive 
protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 
107:671-4. 
94. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in 
cardiovascular risk prediction models for women. Ann Intern Med 2006; 
145:21-9. 
95. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. 
Inflammation, aspirin, and the risk of cardiovascular disease in apparently 
healthy men. N Engl J Med 1997; 336:973-9. 
96. Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, 
fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012; 
367:1310-20. 
97. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and 
cardiovascular disease: application to clinical and public health practice: A 
statement for healthcare professionals from the Centers for Disease Control 
and Prevention and the American Heart Association. Circulation 2003; 
107:499-511. 
98. Iber C, Ancoli-Israel S, Chesson A, Quan S, for the American Academy of 
Sleep Medicine. The AASM manual for the scoring of sleep and associated 
events: rules, terminology and technical specifications. 1st edition. 
Westchester, IL: American Academy of Sleep Medicine, 2007. 
99. Saenger AK, Beyrau R, Braun S, et al. Multicenter analytical evaluation of a 
high-sensitivity troponin T assay. Clin Chim Acta 2011; 412:748-54. 
100. Eggers KM, Lagerqvist B, Venge P, Wallentin L, Lindahl B. Persistent 
cardiac troponin I elevation in stabilized patients after an episode of acute 
coronary syndrome predicts long-term mortality. Circulation 2007; 116:1907-
14. 
101. Uettwiller-Geiger D, Wu AH, Apple FS, et al. Multicenter evaluation of an 
automated assay for troponin I. Clin Chem 2002; 48:869-76. 
102. Christenson RH, Vollmer RT, Ohman EM, et al. Relation of temporal creatine 
kinase-MB release and outcome after thrombolytic therapy for acute 
myocardial infarction. TAMI Study Group. Am J Cardiol 2000; 85:543-7. 
103. Turer AT, Mahaffey KW, Gallup D, et al. Enzyme estimates of infarct size 
correlate with functional and clinical outcomes in the setting of ST-segment 
elevation myocardial infarction. Curr Control Trials Cardiovasc Med 2005; 
6:12. 
104. Vollmer RT, Christenson RH, Reimer K, Ohman EM. Temporal creatine 
kinase curves in acute myocardial infarction. Implications of a good empiric 
fit with the log-normal function. Am J Clin Pathol 1993; 100:293-8. 
105. Todd J, Freese B, Lu A, et al. Ultrasensitive flow-based immunoassays using 
single-molecule counting. Clin Chem 2007; 53:1990-5. 
 57 
106. Apple FS, Simpson PA, Murakami MM. Defining the serum 99th percentile in 
a normal reference population measured by a high-sensitivity cardiac troponin 
I assay. Clin Biochem 2010; 43:1034-6. 
107. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac 
troponin assays. Clin Chem 2012; 58:54-61. 
108. Dati F, Schumann G, Thomas L, et al. Consensus of a group of professional 
societies and diagnostic companies on guidelines for interim reference ranges 
for 14 proteins in serum based on the standardization against the 
IFCC/BCR/CAP Reference Material (CRM 470). International Federation of 
Clinical Chemistry. Community Bureau of Reference of the Commission of 
the European Communities. College of American Pathologists. Eur J Clin 
Chem Clin Biochem 1996; 34:517-20. 
109. Masson S, Latini R, Anand IS, et al. Prognostic value of changes in N-
terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure 
Trial). J Am Coll Cardiol 2008; 52:997-1003. 
110. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural 
history of asymptomatic left ventricular systolic dysfunction in the 
community. Circulation 2003; 108:977-82. 
111. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver 
operating characteristic (ROC) curve. Radiology 1982; 143:29-36. 
112. Pencina MJ, D'Agostino RB Sr., D'Agostino RB Jr., Vasan RS. Evaluating the 
added predictive ability of a new marker: from area under the ROC curve to 
reclassification and beyond. Stat Med 2008; 27:157-72. 
113. Pencina MJ, D'Agostino RB Sr., D'Agostino RB Jr., Vasan RS. Comments on 
integrated discrimination and net reclassification improvements – practical 
advice. Stat Med 2008; 27:207–212. 
114. Remler D, Van Ryzin G. Research Methods in Practice: Strategies for 
Description and Causation. 2nd edition. Thousand Oaks, CA: SAGE 
Publications Inc., 2014. 
115. Dickson W, Roethlisberger F. Management and the Worker. Cambridge, MA: 
Harvard University Press, 1939. 
116. Carlson MD, Morrison RS. Study design, precision, and validity in 
observational studies. J Palliat Med 2009; 12:77-82. 
117. Ho PM, Peterson PN, Masoudi FA. Evaluating the evidence: is there a rigid 
hierarchy? Circulation 2008; 118:1675-84. 
118. Taleb N. Fooled by Randomness. 1st edition. New York, NY: W. W. Norton 
& Company, 2001. 
119. Gustafsson F, Atar D, Pitt B, Zannad F, Pfeffer MA. Maximizing scientific 
knowledge from randomized clinical trials. Am Heart J 2010; 159:937-43. 
120. Jortveit J, Govatsmark RE, Digre TA, et al. Myocardial infarction in Norway 
in 2013. Tidsskr Nor Laegeforen 2014; 134:1841-6. 
121. Apple FS. Counterpoint: Standardization of cardiac troponin I assays will not 
occur in my lifetime. Clin Chem 2012; 58:169-71. 
122. Zaninotto M, Mion MM, Novello E, et al. Precision performance at low levels 
and 99th percentile concentration of the Access AccuTnl assay on two 
different platforms. Clin Chem Lab Med 2009; 47:367-71. 
123. Nilsen T, Sundstrom J, Lind L, Larsson A. Serum calprotectin levels in elderly 
males and females without bacterial or viral infections. Clin Biochem 2014; 
47:1065-8. 
 58 
124. Røsjø H, Omland T. New statistical methods for the evaluation of 
cardiovascular risk markers: what the clinician should know. Clin Sci (Lond) 
2009; 117:13-5. 
125. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of 
prediction models: a framework for traditional and novel measures. 
Epidemiology 2010; 21:128-38. 
126. Katus HA, Remppis A, Looser S, Hallermeier K, Scheffold T, Kubler W. 
Enzyme linked immuno assay of cardiac troponin T for the detection of acute 
myocardial infarction in patients. J Mol Cell Cardiol 1989; 21:1349-53. 
127. Cummins B, Auckland ML, Cummins P. Cardiac-specific troponin-I 
radioimmunoassay in the diagnosis of acute myocardial infarction. Am Heart J 
1987; 113:1333-44. 
128. Omland T, de Lemos JA, Sabatine MS, et al. A sensitive cardiac troponin T 
assay in stable coronary artery disease. N Engl J Med 2009; 361:2538-47. 
129. Hallén J. Troponin for the estimation of infarct size: what have we learned? 
Cardiology 2012; 121:204-12. 
130. Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a 
highly sensitive assay predicts coronary heart disease, heart failure, and 
mortality in the Atherosclerosis Risk in Communities Study. Circulation 2011; 
123:1367-76. 
131. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T 
detected with a highly sensitive assay and cardiac structure and mortality risk 
in the general population. JAMA 2010; 304:2503-12. 
132. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial 
measures of cardiac troponin T using a sensitive assay with incident heart 
failure and cardiovascular mortality in older adults. JAMA 2010; 304:2494-
502. 
133. Omland T, Pfeffer MA, Solomon SD, et al. Prognostic value of cardiac 
troponin I measured with a highly sensitive assay in patients with stable 
coronary artery disease. J Am Coll Cardiol 2013; 61:1240-9. 
134. Hamm CW, Giannitsis E, Katus HA. Cardiac troponin elevations in patients 
without acute coronary syndrome. Circulation 2002; 106:2871-2. 
135. Jeremias A, Gibson CM. Narrative review: alternative causes for elevated 
cardiac troponin levels when acute coronary syndromes are excluded. Ann 
Intern Med 2005; 142:786-91. 
136. Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma 
concentrations of troponin T in patients with stable chronic heart failure. 
Circulation 2007; 116:1242-9. 
137. Mills NL, Churchhouse AM, Lee KK, et al. Implementation of a sensitive 
troponin I assay and risk of recurrent myocardial infarction and death in 
patients with suspected acute coronary syndrome. JAMA 2011; 305:1210-6. 
138. Lyck Hansen M, Saaby L, Nybo M, et al. Discordant diagnoses of acute 
myocardial infarction due to the different use of assays and cut-off points of 
cardiac troponins. Cardiology 2012; 122:225-9. 
139. Agewall S, Eurenius L, Hofman-Bang C, et al. Myocardial infarction with 
angiographically normal coronary arteries. Atherosclerosis 2011; 219:10-4. 
140. Jaffe AS, Apple FS, Morrow DA, Lindahl B, Katus HA. Being rational about 
(im)precision: a statement from the Biochemistry Subcommittee of the Joint 
European Society of Cardiology/American College of Cardiology 
 59 
Foundation/American Heart Association/World Heart Federation Task Force 
for the definition of myocardial infarction. Clin Chem 2010; 56:941-3. 
141. Aakre KM, Sandberg S. Can changes in troponin results be useful in 
diagnosing myocardial infarction? Clin Chem 2010; 56:1047-9. 
142. Eggers KM, Jaffe AS, Venge P, Lindahl B. Clinical implications of the change 
of cardiac troponin I levels in patients with acute chest pain - an evaluation 
with respect to the Universal Definition of Myocardial Infarction. Clin Chim 
Acta 2011; 412:91-7. 
143. Wu AH, Jaffe AS, Apple FS, et al. National Academy of Clinical 
Biochemistry laboratory medicine practice guidelines: use of cardiac troponin 
and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for 
etiologies other than acute coronary syndromes and heart failure. Clin Chem 
2007; 53:2086-96. 
144. Reichlin T, Irfan A, Twerenbold R, et al. Utility of absolute and relative 
changes in cardiac troponin concentrations in the early diagnosis of acute 
myocardial infarction. Circulation 2011; 124:136-45. 
145. Kavsak PA, MacRae AR, Lustig V, et al. The impact of the ESC/ACC 
redefinition of myocardial infarction and new sensitive troponin assays on the 
frequency of acute myocardial infarction. Am Heart J 2006; 152:118-25. 
146. Apple FS, Pearce LA, Smith SW, Kaczmarek JM, Murakami MM. Role of 
monitoring changes in sensitive cardiac troponin I assay results for early 
diagnosis of myocardial infarction and prediction of risk of adverse events. 
Clin Chem 2009; 55:930-7. 
147. Eitel I, Wöhrle J, Suenkel H, et al. Intracoronary compared with intravenous 
bolus abciximab application during primary percutaneous coronary 
intervention in ST-segment elevation myocardial infarction: cardiac magnetic 
resonance substudy of the AIDA STEMI trial. J Am Coll Cardiol 2013; 
61:1447-54. 
148. Byrne RA, Ndrepepa G, Braun S, et al. Peak cardiac troponin-T level, 
scintigraphic myocardial infarct size and one-year prognosis in patients 
undergoing primary percutaneous coronary intervention for acute myocardial 
infarction. Am J Cardiol 2010; 106:1212-7. 
149. Chia S, Senatore F, Raffel OC, Lee H, Wackers FJ, Jang IK. Utility of cardiac 
biomarkers in predicting infarct size, left ventricular function, and clinical 
outcome after primary percutaneous coronary intervention for ST-segment 
elevation myocardial infarction.JACC Cardiovasc Interv 2008; 1:415-23. 
150. Hallén J, Buser P, Schwitter J, et al. Relation of cardiac troponin I 
measurements at 24 and 48 hours to magnetic resonance-determined infarct 
size in patients with ST-elevation myocardial infarction. Am J Cardiol 2009; 
104:1472-7. 
151. Steen H, Giannitsis E, Futterer S, Merten C, Juenger C, Katus HA. Cardiac 
troponin T at 96 hours after acute myocardial infarction correlates with infarct 
size and cardiac function. J Am Coll Cardiol 2006; 48:2192-4. 
152. Boden H, Ahmed TA, Velders MA, et al. Peak and fixed-time high-sensitive 
troponin for prediction of infarct size, impaired left ventricular function, and 
adverse outcomes in patients with first ST-segment elevation myocardial 
infarction receiving percutaneous coronary intervention. Am J Cardiol 2013; 
111:1387-93. 
153. Hallén J, Jensen JK, Fagerland MW, Jaffe AS, Atar D. Cardiac troponin I for 
the prediction of functional recovery and left ventricular remodelling 
 60 
following primary percutaneous coronary intervention for ST-elevation 
myocardial infarction. Heart 2010; 96:1892-7. 
154. Hassan AK, Bergheanu SC, Hasan-Ali H, et al. Usefulness of peak troponin-T 
to predict infarct size and long-term outcome in patients with first acute 
myocardial infarction after primary percutaneous coronary intervention. Am J 
Cardiol 2009; 103:779-84. 
155. Kurz K, Schild C, Isfort P, Katus HA, Giannitsis E. Serial and single time-
point measurements of cardiac troponin T for prediction of clinical outcomes 
in patients with acute ST-segment elevation myocardial infarction. Clin Res 
Cardiol 2009; 98:94-100. 
156. Ohlmann P, Jaquemin L, Morel O, et al. Prognostic value of C-reactive 
protein and cardiac troponin I in primary percutaneous interventions for ST-
elevation myocardial infarction. Am Heart J 2006; 152:1161-7. 
157. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered 
breathing, sleep apnea, and hypertension in a large community-based study. 
Sleep Heart Health Study. JAMA 2000; 283:1829-36. 
158. Seicean S, Kirchner HL, Gottlieb DJ, et al. Sleep-disordered breathing and 
impaired glucose metabolism in normal-weight and overweight/obese 
individuals: the Sleep Heart Health Study. Diabetes Care 2008; 31:1001-6. 
159. Sorajja D, Gami AS, Somers VK, Behrenbeck TR, Garcia-Touchard A, 
Lopez-Jimenez F. Independent association between obstructive sleep apnea 
and subclinical coronary artery disease. Chest 2008; 133:927-33. 
160. Gami AS, Svatikova A, Wolk R, et al. Cardiac troponin T in obstructive sleep 
apnea. Chest 2004; 125:2097-100. 
161. Oktay B, Akbal E, Firat H, Ardic S, Akdemir R, Kizilgun M. Evaluation of 
the relationship between heart type fatty acid binding protein levels and the 
risk of cardiac damage in patients with obstructive sleep apnea syndrome. 
Sleep Breath 2008; 12:223-8. 
162. Einvik G, Røsjø H, Randby A, et al. Severity of obstructive sleep apnea is 
associated with cardiac troponin I concentrations in a community-based 
sample: data from the Akershus Sleep Apnea Project. Sleep 2014; 37:1111-6. 
163. Querejeta Roca G, Redline S, Punjabi N, et al. Sleep apnea is associated with 
subclinical myocardial injury in the community. The ARIC-SHHS study. Am 
J Respir Crit Care Med 2013; 188:1460-5. 
164. Randby A, Namtvedt SK, Einvik G, et al. Obstructive sleep apnea is 
associated with increased high-sensitivity cardiac troponin T levels. Chest 
2012; 142:639-46. 
165. Shah N, Redline S, Yaggi HK, et al. Obstructive sleep apnea and acute 
myocardial infarction severity: ischemic preconditioning? Sleep Breath 2013; 
17:819-26. 
166. Zong P, Setty S, Sun W, et al. Intermittent hypoxic training protects canine 
myocardium from infarction. Exp Biol Med (Maywood) 2004; 229:806-12. 
167. Lavie L, Lavie P. Coronary collateral circulation in sleep apnea: a 
cardioprotective mechanism? Chest 2010; 137:511-2. 
168. Steiner S, Schueller PO, Schulze V, Strauer BE. Occurrence of coronary 
collateral vessels in patients with sleep apnea and total coronary occlusion. 
Chest 2010; 137:516-20. 
169. Røsjø H, Kravdal G, Høiseth AD, et al. Troponin I measured by a high-
sensitivity assay in patients with suspected reversible myocardial ischemia: 
 61 
data from the Akershus Cardiac Examination (ACE) 1 study. Clin Chem 2012; 
58:1565-73. 
170. Tjora S, Gjestland H, Mordal S, Agewall S. Troponin rise in healthy subjects 
during exercise test. Int J Cardiol 2011; 151:375-6. 
171. Kurz K, Giannitsis E, Zehelein J, Katus HA. Highly sensitive cardiac troponin 
T values remain constant after brief exercise- or pharmacologic-induced 
reversible myocardial ischemia. Clin Chem 2008; 54:1234-8. 
172. Ungerer JP, Marquart L, O'Rourke PK, Wilgen U, Pretorius CJ. Concordance, 
variance, and outliers in 4 contemporary cardiac troponin assays: implications 
for harmonization. Clin Chem 2012; 58:274-83. 
173. Labugger R, Organ L, Collier C, Atar D, Van Eyk JE. Extensive troponin I 
and T modification detected in serum from patients with acute myocardial 
infarction. Circulation 2000; 102:1221-6. 
174. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and 
T assay 99th percentile values from a common presumably healthy population. 
Clin Chem 2012; 58:1574-81. 
175. Collinson PO, Heung YM, Gaze D, et al. Influence of population selection on 
the 99th percentile reference value for cardiac troponin assays. Clin Chem 
2012; 58:219-25. 
176. Kim J, Bhattacharjee R, Snow AB, Capdevila OS, Kheirandish-Gozal L, 
Gozal D. Myeloid-related protein 8/14 levels in children with obstructive sleep 
apnoea. Eur Respir J 2010; 35:843-50. 
177. Kim J, Lee S, Bhattacharjee R, Khalyfa A, Kheirandish-Gozal L, Gozal D. 
Leukocyte telomere length and plasma catestatin and myeloid-related protein 
8/14 concentrations in children with obstructive sleep apnea. Chest 2010; 
138:91-9. 
178. Arnardottir ES, Maislin G, Schwab RJ, et al. The interaction of obstructive 
sleep apnea and obesity on the inflammatory markers C-reactive protein and 
interleukin-6: the Icelandic Sleep Apnea Cohort. Sleep 2012; 35:921-32. 
179. Punjabi NM, Beamer BA. C-reactive protein is associated with sleep 
disordered breathing independent of adiposity. Sleep 2007; 30:29-34. 
180. Sharma SK, Mishra HK, Sharma H, et al. Obesity, and not obstructive sleep 
apnea, is responsible for increased serum hs-CRP levels in patients with sleep-
disordered breathing in Delhi. Sleep Med 2008; 9:149-56. 
181. Svensson M, Venge P, Janson C, Lindberg E. Relationship between sleep-
disordered breathing and markers of systemic inflammation in women from 
the general population. J Sleep Res 2012; 21:147-54. 
182. Arcari A, Zito F, Di Castelnuovo A, et al. C reactive protein and its 
determinants in healthy men and women from European regions at different 
risk of coronary disease: the IMMIDIET Project. J Thromb Haemost 2008; 
6:436-43. 
183. Fredrikson GN, Hedblad B, Nilsson J-Å, Alm R, Berglund G, Nilsson J. 
Association between diet, lifestyle, metabolic cardiovascular risk factors, and 
plasma C-reactive protein levels. Metabolism 2004; 53:1436-42. 
184. Fröhlich M, Imhof A, Berg G, et al. Association between C-reactive protein 
and features of the metabolic syndrome: a population-based study. Diabetes 
Care 2000; 23:1835-9. 
185. Edgeworth J, Gorman M, Bennett R, Freemont P, Hogg N. Identification of 
p8,14 as a highly abundant heterodimeric calcium binding protein complex of 
myeloid cells. J Biol Chem 1991; 266:7706-13. 
 62 
186. Razzouk L, Fusaro M, Esquitin R. Novel biomarkers for risk stratification and 
identification of life-threatening cardiovascular disease: troponin and beyond. 
Curr Cardiol Rev 2012; 8:109-15. 
187. Mirrakhimov AE. Obstructive sleep apnea and preclinical cardiac damage: 
need for U.S. representative study sample. Am J Respir Crit Care Med 2014; 
189:868-9. 
188. Nadeem R, Molnar J, Madbouly EM, et al. Serum inflammatory markers in 
obstructive sleep apnea: a meta-analysis. J Clin Sleep Med 2013; 9:1003-12. 
 
